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“By three methods we may learn wisdom:  
First, by reflection, which is noblest;  
second, by imitation, which is easiest;  
and third, by experience, which is the bitterest.”  
-Confucius 
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°C   degrees Celsius 
3’   three prime end of DNA sequences 
5’   five prime end of DNA sequences 
A   adenosine 
ACTH  adrenocorticotrophin 
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FFA   free fatty acid 
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FOXO1  forkhead-O transcription factor 1 
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G6P   glucose-6-phosphatase 
GABA  gamma-aminobutyric acid 
GFP   green fluorescent protein 
GH   growth hormone 
GHRH  GH-releasing hormone 
GHRHR  GHRH receptor 
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GLUT4  glucose transporter 4 
GTT   glucose tolerance test 
Gusb   glucuronidase beta 
h   hour 
H&E   hematoxylin/eosin 
HCl   hydrochloric acid 
HEPES  N-2-hydroxyethylpiperazine-N’-2-ethansulfonic acid 
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IRS   insulin receptor substrate 
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1 Introduction 
1.1 The obesity pandemic and associated diseases 
The worldwide increase in obesity has reached pandemic proportions, as indicated by 
more than 1.6 billion people being overweight and 400 million being obese (1). 
Approximately 50% of American citizen have a body mass index (BMI = weight/size in 
meters²) higher than 25 and are thus considered overweight; a steady increase of average BMI 
has also been reported in Europe, Asia and even Africa (2, 3). In Germany, more than 20% of 
adult men and women are obese as indicated by an BMI greater than 30 (4). Importantly, 
increases in BMI are not only seen in people already overweight or obese. Analysis of the 
BMI distribution over the last 60 years indicates a significant shift among lean, normal weight 
and overweight people of all ages towards an increased BMI, emphasising the reach of the 
obesity pandemic (5). Obesity is the principal consequence of increased neutral lipid storage 
in adipocytes in the white adipose tissue due to either increased energy intake, reduced energy 
expenditure, or both (6-8). In addition to psychosocial effects such as stigmatisation and 
social isolation, obesity increases the risk for contracting a variety of diseases such as cancer, 
atherosclerosis, dyslipidemia, retinopathy, renal failure, neuropathy and especially diabetes 
mellitus (DM), establishing the “metabolic syndrome” (9-14). Economic costs are immense; 
estimated 20% of the US health care budget is spent on patients with DM (15). Chronic 
obesity shortens life span; being obese at the age of 40 reduces the predicted life time by up to 
7 years (16). Furthermore, there is evidence that maternal obesity during pregnancy has 
profound effects on body weight of newborns during their adult life, underlining the necessity 
to combat obesity (17-20). In light of these alarming epidemiological findings, considerable 
efforts have been undertaken to understand how body weight and glucose homeostasis are 
regulated in humans. 
 
1.2 Energy homeostasis 
 In healthy humans and mice, a specific body weight is perpetuated, since both 
experimental underfeeding and overfeeding will lead to compensatory changes in food intake 
and energy expenditure (21-24). Therefore, physiological signals exist which contain fat mass 
gain during overabundance, or increase feeding in case of depleted energy stores. These 
physiological signals and circuits are therefore responsible for maintaining energy 
homeostasis. Owing to the obesity pandemic, it has been deducted that body weight gain 
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indicates malfunctioning of these counterregulatory systems, possibly due to genetic 
predisposition, environmental factors or most likely, both (25-27). From an evolutionary point 
of view, the ability to sustain body weight in a scarce environment has been very important, 
since energy surplus was ultimately very rare until the middle of the 20th century (the “thrifty 
gene” hypothesis) (28). The hypothesis that signals, for example hormones, secreted by 
peripheral tissues might have an effect on central/neuronal circuits to control body weight has 
been highlighted by findings from the late 20th century. These studies indicated that multiple 
feedback loops between the brain and peripheral tissues regulating energy homeostasis exist, 
with the hormones insulin and leptin implicated as the most important regulators of body 
weight and glucose metabolism (29-32). 
 
1.3 The adipokine leptin 
The gene of the critical regulator of energy homeostasis, leptin, was cloned in 1995 
(33). Leptin is expressed mainly in the adipose tissue in relation to the stored fat content, and 
released into the circulation (34). It was identified after genetic screening of a mouse strain 
called the obese/obese (ob/ob) mouse, which was revealed to completely lack leptin protein 
due to a homozygous mutation (33). Later on, human patients were identified which also lack 
circulating leptin and hence show early-onset morbid obesity, underscoring the importance of 
leptin in human physiology (35). The leptin receptor (ObR) was subsequently cloned, and 
mice lacking the signalling isoform of the leptin receptor (ObRb) show massive obesity, and 
develop early onset DM, and are thus called db/db mice (from diabetic) (36, 37). Application 
of recombinant leptin to ob/ob mice or human patients lacking leptin rapidly normalises body 
weight and glucose homeostasis (33). Nonetheless, the overwhelming majority of obese 
patients cannot be treated by leptin, since obese patients (and obese animal models) show 
increased levels of leptin in the circulation, indicating a leptin resistant state. So far, the 
search for an leptin sensitizing drug with efficacy in patients has been fruitless (38).  
 
1.4 Leptin signalling 
Leptin signals by activation of its receptor which is expressed at high levels in several 
brain regions, especially the hypothalamus (36, 39).  It has been demonstrated that the weight-
reducing effects of leptin are predominantly mediated by its action on neurons (40). 
Activation of its receptor leads to recruitment of janus kinases (JAK) 2, which phosphorylate 
the intracellular domain on specific residues (41). JAK2 is able to phosphorylate the 
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transcription factor signal transducer and activator of transcription (STAT) 3 , which after 
homodimerisation enters the nucleus to activate or inactivate transcription of leptin-regulated 
genes by recruitment of histone acetylases or deacetylases, respectively (37, 42). Besides 
several phosphatases implicated in dephosphorylation of leptin signalling cascade proteins 
(43), suppressor of cytokine signalling (SOCS) 3 has been shown to be crucial for leptin 
signalling. Its expression is positively regulated by leptin stimulation, thus leptin increases 
expression of its own negative regulator, which subsequently reduces interaction of STAT3 
with the ObRb and thus enables a new round of stimulation (41, 43). Importantly, it has been 
shown that a chronic hyperleptinemic state induces a disproportional increase in SOCS3 
expression, possibly indicating that chronic leptin signalling by itself induces leptin resistance 
(44). In addition to JAK2/STAT3 signalling, leptin is able to activate insulin´s main signalling 
cascade phosphatidyl-inositol-3-kinase (PI3K) through the adapter protein SH2-B (45), 
although duration and signal strength of PI3K activation is considerably lower compared to 
insulin (46-50).  
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Figure 1: Canonical leptin signalling.  
Binding of leptin leads to recruitment of Jak2, autophosphorylation and phosphorylation of ObRb. After Jak2-
mediated phosphorylation of STAT3, pSTAT3 dimers activate transcription of target genes by recruitment of 
histone acetylases. One of these genes is SOCS3, and the SOCS3 protein in a feedback loop binds to JAK2 and 
thereby inhibits STAT3 phosphorylation. In addition, JAK2 is able to directly activate IRS/PI3K signalling, 
leading to AKT activation. IRS, insulin receptor substrate; JAK2, Janus kinase 2; ObRb, long form of leptin 
receptor; PDK1, 3-phosphoinositide-dependent protein kinase 1; PI3K, phosphatidylinositol-3-kinase; PIP2, 
phosphatidyl-inositol-4,5-bisphosphate; PIP3, phosphatidylinositol-3,4,5-triphosphate; SOCS3, suppressor of 
cytokine signalling 3; STAT3, signal transducer and activator of transcription 3. 
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1.5 The pancreatic hormone insulin 
The notion that a pancreatic hormone is able to acutely reduce glucose concentration 
in the blood has been known for more than 80 years, following extraction of insulin from dog 
pancreas by Banting and Best (51). In pancreatic β-cells, insulin is translated as a 51 amino 
acid preproprotein, which after cleavage of a signalpeptide as well as generation of disulfide 
bridges in the endoplasmatic reticulum (ER), is stored in cytoplasmatic vesicles (52, 53). If 
ambient glucose concentrations rise, glucose enters the cell via glucose transporter (GLUT) 2 
and is metabolised into adenosine triphosphate (ATP). Rising intracellular ATP 
concentrations are sensed by ATP-dependent potassium (KATP) channels, which close at a 
certain ATP concentration threshold. Closure of KATP channels depolarises the membrane of 
the β-cell, resulting in the opening of calcium channels, allowing Ca2+ ion influx. The 
increasing intracellular Ca2+ concentrations induce vesicle exocytosis and thus release of 
insulin into the bloodstream (52, 54). 
 
1.6 Insulin signalling 
The insulin signalling cascade is activated by binding of insulin to the insulin receptor 
(IR), which is almost ubiquitously expressed in mammalian tissues, including hepatocytes, 
myocytes, adipocytes, pancreatic cells, several lineages of the immune system, and the brain 
(55-60). It consists of two heterodimers of the α- and β-chain, wherein the α-chain is located 
extracellular, while the β-chain spans from the extracellular through the membrane into the 
intracellular space (61). Binding of insulin to the IR elicits a conformational change, which 
actives the tyrosine kinase activity of the β-chain (61). After trans phosphorylation of the β- 
chains at seven tyrosine residues, maximal kinase activity is achieved (61). Insulin receptor 
substrates (IRS) bind to the IR via their phosphotyrosine binding domains (PTB) (62-64). 
Most of the IRS proteins also contain a pleckstrin homology (PH) domain, which allows 
interaction with phospholipids in the membrane, ensuring co-localization of the IR and its 
downstream targets (62). There are at least five known IRS proteins, although the role of 
IRS1 and IRS2 is best described (65). After phosphorylation, IRS proteins serve as docking 
platforms for proteins containing a Rous sarcoma virus (Src)-homology (SH) 2 domain, for 
example growth factor receptor-bound protein (Grb), the SH2 domain containing protein 
tyrosine phosphatase 2 (Shp2) , and importantly, the regulatory subunit p85 of PI3K (66-68).  
While Grb subsequently mediates activation of the mitogen activated protein kinase (MAPK) 
pathway which regulates cell growth and mitosis (69), PI3K activation mediates the majority 
of insulin´s effects on glucose and lipid metabolism (68, 70, 71). Activity of the catalytic 
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subunit p110 is inhibited by the regulatory subunit p85, until p85 binds to phosphorylated 
tyrosine residues of IRS protein by its SH2 domain (68, 70). This leads to conformational 
changes, allowing activation of the p110 subunit. Subsequently, PI3K mediates the 
conversion of the membrane lipid phosphatidyl-inositol-4,5-bisphosphate (PIP2) to 
phosphatidyl-inositol-3,4,5-trisphosphate (PIP3) (68). Accumulation of PIP3 in the plasma 
membrane leads to recruitment of 3-phosphoinositide-dependent protein kinase (PDK) 1, 
which binds to PIP3 by its PH domain (72). PDK1 phosphorylates protein kinase B (PKB, 
also known as AKT) isoforms, which regulates the activation of downstream targets such as 
glycogen-synthase-kinase (GSK) 3, tuberin, S6 and mouse double minute (mdm) 2, which are 
themselves crucial regulators of glycogen synthesis, translation and cell survival, respectively 
(72-76).  
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Figure 2: Canonical insulin signalling.  
Binding of insulin leads to a conformational change of the IR, ending in activation of the endogenous kinase 
ability. After autophosphorylation of the IR, IRS proteins bind to the phosphorylated residues by their SH2 
domains, and are themselves phosphorylated by the IR. Grb binds via its SH2 domain, eliciting activation of the 
Ras-Raf-MAPK signalling pathway, which mediates some of insulin´s effects on growth. Phosphorylation of 
IRS proteins allows binding of p85, the regulatory subunit of the PI3K complex. This de-inhibits p110, the 
catalytic subunit of PI3K, which subsequently phosphorylates the membrane lipid PIP2 to generate PIP3. PIP3 
accumulation in turn will recruit and allow binding of both PDK1 and AKT via their PH domains. After co-
localisation induced by PIP3 binding, PDK1 phosphorylates and thereby activates AKT, which mediates most of 
insulin´s effect on glucose and glycogen metabolism, as well as activating protein translation and gene 
transcription. Grb, growth factor receptor bound; IR, insulin receptor; IRS, insulin receptor substrate; MAPK, 
mitogen-activated protein kinase; P, activating phosphorylation at threonine or tyrosine residues; PDK1, 3-
phosphoinositide-dependent protein kinase 1; PI3K, phosphatidylinositol-3-kinase; PIP2, phosphatidyl-inositol-
4,5-bisphosphate; PIP3, phosphatidylinositol-3,4,5-triphosphate; Ras, Rat sarcoma protein; Sos, son of 
sevenless. 
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Besides the important role in activation of AKT, PDK1 has been shown to be essential 
for maturation and activation of several kinases, including protein kinase C (PKC) isoforms 
(72, 77). The crucial role for PDK1 in development and cell cycle control is highlighted by 
the finding that unlike mice null for any one of the AKT isoforms, PDK1 null mice are 
embryonic lethal (78-81).  
Insulin signalling plays a critical role for glucose and lipid dispersal into adipose tissue 
and skeletal muscle. In white adipose tissue (WAT) and muscle, insulin stimulates 
translocation and merge of vesicles containing GLUT4 with the plasma membrane, and 
increases expression of GLUT1 expression in WAT (58, 82). Insulin has a very prominent 
anti-lipolytic effect; it decreases activity of hormone sensitive lipase (HSL) and expression of  
adipocyte triglyceride lipase (ATGL) in WAT (83, 84). In parallel to this anti-lipolytic effect, 
insulin increases expression of key regulators of lipogenesis and lipid uptake, such as fatty 
acid synthase (FAS), and lipoprotein lipase (LPL) (85, 86).  
Besides increasing glucose uptake, insulin also stimulates muscle glycogen synthesis, 
protein synthesis, and inhibits protein breakdown, which is in line with its potent anabolic 
effect on muscle mass (73, 74, 87). 
 The transcription factor forkhead box 01 (FOXO1) is a key target of insulin signalling 
(88). FOXO1 directly controls hepatic expression of genes important for gluconeogenesis, 
such as glucose-6-phosphatase (G6P) and phosphoenolpyruvate carboxykinase (PEPCK) (89-
92). Besides glucose homeostasis, FOXOs modulate expression of genes involved in 
apoptosis, cell cycle progression, oxidative stress response, and DNA repair (88). In line with 
a conserved role of FOXO1, forkhead transcription factors were originally found in 
Drosophila melanogaster, and homologues also exist in Caenorhabditis elegans (93-95). In 
all of these animals as well as in humans, insulin or insulin-like peptides regulate 
forkhead/FOXO localisation by phosphorylation, inducing nuclear export of these proteins 
(88, 93, 94). Interestingly, FOXO homologues also regulate life span in invertebrates (94, 96). 
Here, FOXO homologues induce a transcriptional program which limits growth, increases life 
span and oxidative stress resistance (88). In turn, it has been shown that multiple stressors 
such as starvation activate stress kinases, e.g. JNKs, which positively modulate FOXO 
function by assuring nuclear localisation (88, 97, 98). Importantly, it has been reported, that 
FOXO1 signalling in mice is also important for control of energy homeostasis (see below). 
1.7 The brain as a regulator of energy homeostasis 
 Each physiological activity is directly or indirectly controlled by neuronal circuits. 
Experiments including retrograde tracers studies have demonstrated, that organs involved in 
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regulation of energy homeostasis, such as liver, muscle, adipose tissue, gut or the pancreas, 
are under direct control of the central nervous system (CNS) (99-104). Since the advent of the 
obesity and diabetes pandemic, considerable efforts are underway to understand where 
homeostatic signals such as leptin or insulin act in the CNS to influence feeding behaviour 
and glucose metabolism. Extensive experimental evidence points to a crucial role for the 
hypothalamus in regulation of energy homeostasis (30, 32, 105). Additionally, neurons in 
other brain centers (and neuropeptides/neurotransmitters expressed therein) such as in the 
ventral tegmental area (dopamine) or the raphe nucleus (serotonin) regulate feeding and 
feeding-related behaviour, such as foraging or the rewarding effects of food (106-110). It 
should be noted that all of these neuronal circuits are not isolated from each other, but instead 
are connected by direct synaptic input or via inter-neurons (111-114). 
 
1.8 The hypothalamus as a regulator of energy homeostasis 
 The finding that neuronal populations located in the hypothalamus regulate food 
intake and energy expenditure stems from historical experiments, in which different 
hypothalami nuclei were disrupted by chemical agents or mechanical destruction (115). 
Besides introduction of lesions, the effect of electrical stimulation in different hypothalamic 
nuclei was also studied in animal models (116, 117). These studies defined the lateral 
hypothalamus as a “hunger center” and the ventromedial hypothalamus as a “satiety center”, 
since stimulation of the first increases and of the latter decreases food intake (118-120). In 
addition to regulation of body weight, lesion experiments in rabbits demonstrated that the 
hypothalamus also controls blood glucose levels (121). Nonetheless, it has been noted that in 
these experiments, during the introduction of the chemicals or electrodes into the 
hypothalamus, brain regions located above the hypothalamus may be damaged, chemicals 
may diffuse into other brain nuclei, and cell types apart from neurons are potentially affected 
(122).  
 Although it was then noted that hypothalamic neurons are regulators of feeding, the 
exact efferent and afferent signals to peripheral tissues were still unknown. Following cloning 
of leptin and its receptor, it was established that the hypothalamus shows very high levels of 
ObRb expression (123, 124), and the same is true for insulin receptor mRNA (125, 126). In 
line with this, application of leptin, insulin or insulin mimetics into the hypothalamus or 
intracerebroventricular (icv) injection into the adjacent third ventricle acutely reduced food 
intake and body weight, whereas ablation of the leptin or insulin receptor in this region 
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increased body weight (46, 127-129). Henceforth, it was attempted to identify the neuron 
population(s) involved in mediating insulin´s and leptin´s effect on energy homeostasis. 
 The hypothalamus consists of several nuclei, including the arcuate nucleus (Arc), the 
ventromedial nucleus of the hypothalamus (VMH), the dorsomedial nucleus (DMH), and the 
paraventricular nucleus (PVN). The Arc located next to the third ventricle is privileged among 
these nuclei due to its close contact with the median eminence, a site characterized by an 
incomplete blood brain barrier (BBB) (130). Thus, this location allows neurons to sense acute 
fluctuations of hormones or other signals in the blood. Accordingly, peripheral injection of 
hormones induces rapid (<10 minutes) activation of their signalling cascades in the Arc.  
 Possibly the most extensively studied neuronal populations in the Arc are the 
proopiomelanocortin (POMC) and agouti-related protein (AgRP) / neuropeptide Y (NPY) 
expressing neurons. Several human patients have been found to have mutations in the POMC 
gene, which inhibit normal expression or processing of the preproprotein (131-133). These 
patients suffer from massive early-onset obesity. Conventional POMC knockout mice 
demonstrated the same phenotype, which suggested a conserved role in control of energy 
homeostasis both in animal models and humans (132-135). In the hypothalamus, POMC is 
expressed in ~3000 neurons in the Arc (with very few in the PVN), which are consequently 
called POMC neurons. In these neurons, the POMC pro-protein is cleaved to generate the 
neuropeptide alpha-melanocyte stimulating hormone (α-MSH), which after secretion binds to 
and activates the melanocortin receptor 4 (MC4R), which is expressed on secondary neuronal 
populations, located in the PVN of the hypothalamus, among other nuclei (136, 137). Thus, 
electrical stimulation leads to membrane depolarisation of POMC neurons, α-MSH release, 
MC4R activation and ultimately decreases food intake and increases energy expenditure.  In 
line with these findings, mutations in all proteins involved in processing, release or signalling 
of the so-called melanocortin pathway have been found in humans, which usually lead to 
early-onset obesity (138-140). However, both the downstream pathways and the nature of the 
MC4R expressing neurons are only incompletely understood. 
POMC is also expressed in two cell types of the pituitary, namely corticotrophs and 
melanotrophs. Upon stress stimuli, PVN neurons release corticotrophin releasing hormone 
(CRH) onto pituitary corticotrophs, which produce and secrete the POMC cleavage product 
adrenocorticotrophic hormone (ACTH). ACTH stimulates release of glucocorticoids, i.e. 
corticosterone (in rodents) or cortisol (in humans) by the adrenal gland (141-143). 
Glucocorticoids have profound effects on physiological circuits which include antagonistic 
effects on insulin signalling and immune cell function. Importantly, glucocorticoids are 
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necessary to prevent exaggerated stress response (144). In turn, human patients (and mice) 
without circulating glucocorticoids will die from extreme stressors such as surgery (144).  
Melanotroph-released α-MSH modulates hair and skin pigmentation (145). Since 
POMC null mice show only very faint changes in skin color, the relative importance of 
melanocortins in mice with regard to pigmentation appears to be smaller compared to the 
situation in humans (134). 
 In contrast to the anorexigenic effect of melanocortin neuropeptides, NPY and AgRP 
release by AgRP/NPY neurons procure orexigenic effects. As the name suggests, these 
neurons co-express AgRP/NPY and are located in close vicinity to POMC neurons in the Arc 
(146). While NPY binds to one of five different receptors on target neurons and thus can 
indirectly counteract the anorexigenic action of leptin or insulin, AgRP as an inverted agonist 
directly blocks α-MSH mediated activation of the MC4R, thus inhibiting α-MSH action (147, 
148). Supporting the critical role of AgRP/NPY on food intake, acute ablation of AgRP/NPY 
neurons in adult mice leads to starvation (149, 150). Many hormones implicated in control of 
energy homeostasis such as leptin and insulin have been shown to affect POMC and AgRP 
neuron function, for example by modulating POMC/AgRP mRNA expression or 
POMC/AgRP neuron excitability (48, 151-154).  
 
1.9 Leptin, insulin and the melanocortin circuit 
 In 1979, Woods and colleagues demonstrated insulin´s ability to decrease food intake 
and body weight in baboons when injected icv, and 21 years later mice lacking insulin 
receptors only in the central nervous system were found to develop diet-sensitive obesity (56, 
155).  When it was demonstrated that insulin´s ability to decrease food intake was dependent 
on the melanocortin system, attention was directed to the molecular underpinnings of 
insulin´s regulation of neurons and neuropeptides in the melanocortin circuit (156). Icv 
injection of insulin increases POMC mRNA expression levels in fasted animals, while mice 
lacking IRS2 show a decrease in hypothalamic POMC expression (156-158). Moreover, 
insulin negatively modulates NPY mRNA expression (159). In line with these findings, 
insulin activates PI3K signalling in identified POMC and AgRP neurons (154). Kitamura and 
colleagues suggested, that FOXO1 is a negative regulator of POMC and a positive regulator 
of AgRP expression, and that PI3K activation led to FOXO1 phosphorylation and nuclear 
export, therefore allowing POMC transcription to take place and blocking AgRP expression 
in vitro (42). Another group independently presented the same results, but also provided 
evidence for a modulating role of FOXO1 in expression of NPY (50). Additionally, it has 
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been reported that FOXO1 negatively regulates the expression of Carboxypeptidase E (CPE), 
which is involved in POMC cleavage into α-MSH (160). Nonetheless, most of these findings 
were based on either short-term studies following icv injections, or on cell line-based in vitro 
experiments.  
 Könner and colleagues therefore decided to ablate the insulin receptor in POMC 
(denoted as IRΔPOMC mice) or AgRP neurons (IRΔAgRP mice) using the Cre/loxP system. 
Interestingly, mice lacking IR on POMC or on AgRP neurons did not show differences in 
body weight, food intake, leptin levels, hypothalamic POMC mRNA expression or glucose 
tolerance, possibly due to compensation for the lack of insulin input by unknown mechanisms 
(151). On the other hand, the authors demonstrated an important role for IR signalling in 
AgRP neurons in control of glucose metabolism, since IRΔAgRP mice showed incomplete 
suppression of HGP under hyperinsulinemic conditions (151). This effect was not detected in 
glucose tolerance tests because of compensation by an increase in adipose tissue glucose 
uptake (151). The considerable effect of hypothalamic insulin action on hepatic glucose 
output and peripheral glucose uptake has been independently demonstrated several times, 
although species differences concerning direct hepatic effects and indirect CNS effects of 
insulin on glucose production might exist (161-166).  
 Plum and colleagues decided to further examine the role of insulin-activated, PI3K-
mediated signalling by generating mice lacking the negative regulator of PI3K signalling, the 
phosphatase and tensin homologue (PTEN) in POMC neurons (PTENΔPOMC mice). PTEN 
dephosphorylates PIP3 to generate PIP2 (167). These mice demonstrated increased PIP3 
levels in identified POMC neurons, even under conditions of starvation when circulating 
insulin concentration was low (168). In line with previous results which suggested PI3K 
signalling in control of POMC expression, POMC mRNA levels were increased in young 
PTENΔPOMC mice (168). Surprisingly, these mice unexpectedly developed sex-dimorphic, 
diet-dependent obesity (168). Further analysis revealed that POMC neurons from PTENΔPOMC 
mice were electrically silent, which was due to potassium outflow mediated by KATP 
channels (168). Previously, it had been shown that these KATP channels are sensitive to 
adjacent PIP2/PIP3 concentrations, with PIP3 increasing the probability of KATP channels to 
open (169, 170). The physiologic role of insulin in KATP channel opening was further 
demonstrated by insulin´s ability to hyperpolarize POMC neurons ex vivo (168). This effect is 
not specific to POMC neurons, as AgRP neurons and neuronal cell lines also show 
hyperpolarisation after insulin stimulation (47, 151). Therefore, it was deducted that chronic, 
high level insulin stimulation might lead to hyperpolarisation and electrical silencing of both 
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POMC and AgRP neurons, which challenged the role of these two neuron populations in 
control of energy homeostasis (105, 171). Taken together, although the effect of chronic high 
levels of PI3K activation has thus been studied in a mouse model, the contribution of 
signalling components acting downstream of PI3K, e.g. PDK1 has not been analysed.  
 Concurrent with the finding that insulin stimulation leads to nuclear export of FOXO1, 
leptin stimulation was found to increase STAT3 localisation on the POMC promoter, and 
FOXO1 and STAT3 were found to compete for binding on adjacent sites on the POMC 
promoter (42, 50). The physiologically relevant role of leptin signalling on POMC, AgRP and 
NPY expression is well established (48, 152, 172). Interestingly, leptin´s ability to regulate 
energy homeostasis was shown to be dependent on CNS PI3K signalling, and leptin has been 
shown to be able to activate neuronal PI3K signalling (47, 129, 173).  
 Experiments on leptin´s effect on electrical activity have led to conflicting results. 
Leptin was originally shown to induce POMC firing, whereas others have found no effect or 
inhibition of leptin on neuronal firing (47, 49, 173-175). Adding to the confusion, it was 
demonstrated that leptin´s ability to increase firing of POMC neurons was dependent on PI3K 
signalling (173). It is unknown how activation of the same signalling pathway (PI3K) either 
leads to hyperpolarisation (KATP channel activation, by insulin) or depolarisation (channel(s) 
unknown, by leptin), although magnitude or duration of PI3K stimulation might play into this 
phenomenon (105). Nonetheless, insulin´s ability to hyperpolarise POMC neurons appears to 
be specific to the postnatal adolescent period in mice, since insulin-induced hyperpolarisation 
cannot be detected in POMC neurons of adult mice (A. Husch & P. Kloppenburg, 
unpublished observation). Since virtually all electrophysiological experiments so far have 
been performed on brain slices derived from mice before the time of weaning, the effect of 
leptin and insulin on neuronal excitation in adult mice remains unresolved (105). 
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Figure 3: The melanocortin system regulates energy homeostasis.  
Adiposity signals such as insulin and leptin signal to proopiomelanocortin neurons in the arcuate nucleus of the 
hypothalamus to enhance expression of POMC and/or induce release of α-MSH onto second-order neurons, 
some of which are located in the PVN. α-MSH binds to and activates these neurons via its receptor MC4R. At 
the same time, activation of orexigenic neurons such as AgRP/NPY neurons is inhibited. This de-inhibits POMC 
neurons by a reduction of inhibitory GABAergic input by AgRP/NPY neurons. Hormone and nerve outflow of 
circuits activated by PVN neurons and other second-order neurons inhibits hepatic glucose production, increases 
energy expenditure in BAT, reduces food intake and modulates lipid metabolism in WAT. This leads to fat mass 
loss, which subsequently affects circulating concentrations of the adiposity signals. 3v, third ventricle; α-MSH, 
α-melanocyte stimulating hormone; AgRP, agouti-related protein; ARC, arcuate nucleus of the hypothalamus; 
BAT, brown adipose tissue; GABA, γ-aminobutyric acid; MC4R, melanocortin receptor 4; ME, median 
eminence; NPY, neuropeptide Y; POMC, proopiomelanocortin; PVN, paraventricular nucleus of the 
hypothalamus; WAT, white adipose tissue. Green, POMC neurons; red, AgRP/NPY neurons; yellow, PVN 
neurons. 
 
 
1.10 Lipid-induced insulin and leptin resistance 
 During analysis of leptin´s and insulin´s role in control of neuronal excitation and 
expression of neuropeptides, it has become clear that during conditions of high-energy 
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feeding such as high-fat diet, both signalling cascades show decreased efficacy. Hence, high-
fat feeding for five days leads to a decrease in hypothalamic phospho-STAT3 
immunoreactivity after leptin stimulation (176). In line with this, chronic leptin signalling has 
been shown to induce high levels of SOCS3 expression, which will further exacerbate leptin 
resistance (177, 178). Elevated expression of the phosphatase PTP-1B by high-fat feeding 
have also been implicated in inducing leptin and insulin resistance (179, 180). Although there 
is currently no pharmacological agent known to act as an leptin sensitiser, experimental 
evidence ascribes a high lipid-containing diet to cause CNS leptin and insulin resistance, and 
in turn, a reduction in dietary lipid content is thought to be beneficial for leptin and insulin 
sensitivity in the CNS (181-184). Here, especially saturated fatty acids such as palmitate may 
activate several signalling cascades to reduce leptin and insulin signalling. Several isoforms 
of protein kinase C (PKC) have been shown to negatively modulate insulin sensitivity, which 
are directly activated by diacylglycerols, and hypothalamic diacylglyerol concentration is 
aggravated by a high-fat diet (182, 185). Besides PKC activation, the ability of fatty acids to 
induce leptin and insulin resistance in the CNS and the periphery has been shown to be 
mediated by toll-like receptor (TLR) 2 and 4 signalling. Fatty acids are thought to bind to 
TLRs, although an indirect activation has also been described (186, 187). The evolutionary 
conserved role of TLRs is the recognition of pathogen-associated molecular patterns 
(PAMPS) such as bacterial lipopolysaccharides, and thus TLRs are crucial sensors of the 
innate immune system (188, 189). Mice with loss-of-function mutations in TLR4 have been 
shown to be protected from diet-induced glucose intolerance, and although protection from 
diet-induced obesity has also been reported, some find increased obesity (190-195). Of note, 
activation of TLRs will lead to activation of nuclear factor κ-light chain enhancer of B cells 
(NFκB) as well as c-Jun N-terminal kinase (JNK) signalling (192, 194, 195). 
 
1.11 The role of NFκB and JNK signalling in energy homeostasis 
 The transcription factor NFκB plays an integral part in cells of the immune system 
(196). Consisting of two subunits, the NFκB complex is bound to the inhibitor of NFκB (IκB) 
and thus sequestered in the cytoplasm. Upon divergent stimuli such as cytokines, foreign 
substances or UV irradiation, IκB is phosphorylated by the IκB kinase (IKK) complex, which 
subsequently leads to degradation of IκB. The NFκB complex will now translocate to the 
nucleus, where it regulates transcription of hundreds of genes (196). Under obese conditions, 
NFκB signalling is mildly, but chronically activated (197, 198). IKK signalling can induce 
insulin resistance by serine phosphorylation of IRS proteins, but NFκB activation will also 
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lead to increased production of cytokines such as tumor necrosis factor (TNF) α (197). In line 
with this, mice with increased activation of NFκB signalling in the liver develop glucose 
intolerance and insulin resistance (197). Importantly, NFκB signalling in the hypothalamus is 
a negative regulator of insulin and leptin sensitivity, partially by inducing SOCS-3 expression 
(184, 198).  
 Besides NFκB signalling, the JNK signalling cascade has been shown to be activated 
by diet-induced obesity (199). There are three known JNK homologues, denominated JNK1, 
JNK2 and JNK3 (200). Whereas JNK1 and JNK2 are ubiquitously expressed, JNK3 is most 
abundant in the brain and less in peripheral tissues (200). JNKs are able to regulate 
transcription, survival, apoptosis and other cellular events in response to diverse stimuli such 
as UV irradiation or cytokine stimulation (200). Interestingly, JNK1 plays a role in obesity-
associated pathologies, since conventional JNK1 but not JNK2 knockout mice are protected 
from obesity-induced hyperglycemia, hyperinsulinemia and insulin resistance (199). In this 
context, insulin resistance is caused by JNK1-mediated phosphorylation of specific serine 
residues of IRS proteins (199, 201). These inhibitory phosphorylation events block 
recruitment of IRS proteins to the insulin receptor and thereby activation of downstream 
signalling, causing insulin resistance (202, 203). In addition to protection against diet-induced 
obesity, several physiologic processes are altered in JNK1 null mice, including bone 
remodelling and breeding efficiency, and the outward phenotype of JNK1 mice is likely a 
combination of all of these phenotypes, with most of them unexplored yet (200, 204) 
 Several groups have aimed to define the peripheral tissues in which JNK1 ablation is 
crucial for the protection from high-fat diet (HFD)-mediated impairment of glucose 
metabolism. Recently, mice with JNK1 ablation in the hematopoietic compartment were 
shown to be resistant to diet-induced insulin resistance due to reduced inflammation (205). In 
contrast, other investigators could not find any improvement in systemic glucose homeostasis 
in mice with JNK1 ablation in the hematopoietic compartment or specifically in the myeloid 
lineage (206, 207). Strikingly, fat cell-specific disruption of JNK1 provided evidence for a 
crucial role of adipose tissue JNK1 in systemic glucose metabolism (207). In the light of these 
findings, a role for JNK1 signalling in not yet defined tissues in control of glucose 
homeostasis seems likely, as neither adipose tissue nor myeloid cell-specific JNK1-deficient 
mice exhibit a phenotype comparable to conventional JNK1 knockout mice.  
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Figure 4: Multiple pathomechanisms of insulin resistance.  
Obesity induces hyperlipidemia and chronic, low-level inflammation. This leads to fatty acid-mediated 
activation of TLRs and activates cytokine signalling. In addition, overabundance of lipids and glucose as well as 
the physiologic response to obesity will increase protein synthesis. When the folding capacity of the ER is 
surpassed, unfolded proteins will aggregate, thereby inducing ER stress. These stress response pathways 
eventually lead to activation of JNK1 and IKK signalling, which act as stress sensors. Both JNK and IKK have 
been shown to phosphorylate serine residues on IRS proteins, blocking IR/IRS binding and downstream 
signalling, thus inducing insulin resistance. ER, endoplasmatic reticulum; IKK, IκB kinase; IR, insulin receptor; 
IRS, insulin receptor substrate; JNK1, c-Jun n-terminal kinase 1; TLR, toll-like receptor; TNFα, tumor necrosis 
factor α. 
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1.12 Central and peripheral inflammation and energy homeostasis 
 Obesity induces a chronic, low-grade state of inflammation both in animal models and 
in human patients. Levels of cytokines such as TNFα, interleukin (IL) 6, or acute phase 
proteins such as C-reactive protein (CRP) are increased in the circulation of obese rodents and 
humans (202, 203, 208). WAT and WAT-invading immune cells such as macrophages have 
been shown to be responsible for this low-grade inflammation (203, 208). It is thought that at 
a certain stage during obesity, adipocytes are overloaded with lipids, and activate 
programmed cell death (apoptosis). This attracts circulating macrophages into WAT, which 
can be visualised as so-called crown-like structures in adipose tissue biopsies (209). These 
activated macrophages are distinct from resident macrophages, as indicated by a more pro-
inflammatory expression pattern (210). Cytokine signalling has been shown to induce insulin 
resistance in tissues crucial for energy homeostasis such as liver and adipose tissue, resulting 
in hyperglycemia and hyperlipidemia, which in a feed-forward loop can induce expression of 
pro-inflammatory cytokines (211, 212).  
 Cytokines can pass the BBB (213). Moreover, certain brain nuclei such as the Arc lack 
a dense blood brain barrier, which might imply that circulating cytokines engage pro-
inflammatory signalling in these regions (130). Therefore, it has been investigated if increased 
inflammatory signalling can be detected in hypothalamic tissue from obese animal models. 
These experiments have shown that hypothalamic pro-inflammatory cytokine content is 
increased in diet-induced obesity, although it was not determined if these cytokines are 
produced in an endocrine or paracrine fashion or both (214). In line with this, NFκB 
signalling is increased in the hypothalamus of diet-induced obese mice, and ablation of IKK2 
ameliorates diet-induced obesity (184, 198). Nonetheless, it has not been reported if local 
expression of pro-inflammatory cytokines is increased, for example by microglia, resident 
immune cells akin to macrophages (215). 
 Analysis of the effects of centrally applied TNFα on energy homeostasis has shown 
conflicting results; whereas some investigators find an anorexigenic effect, some do not (216, 
217). It has been noted that during infection, TNFα levels rise by several magnitudes, and that 
this increase might signal in unknown brain regions to induce infection-associated anorexia 
(216-218). 
 The role of IL6 in control of energy homeostasis appears to be highly complex. 
Several groups have reported that IL6, which is released by macrophages/microglia, 
adipocytes, during/after physical activity by muscle tissue, and at very low levels by neurons, 
induces hepatic insulin resistance in vivo and in vitro, while others report a crucial role for 
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hepatic IL6 signalling in improving whole body glucose dispersal (151, 219, 220). 
Nonetheless, conventional IL6 knockout mice show adult-onset obesity, which might indicate 
a role for IL6 in central regulation of body weight control, although CNS-specific IL6 or IL6-
receptor knockout mice have not been generated yet (221).  
 
1.13 ER stress and energy homeostasis 
 Hotamisligil and colleagues first reported that obesity induces hepatic ER stress (222). 
During normal cellular function, protein folding in the endoplasmatic reticulum is assisted by 
chaperones such as glucose-regulated protein (Grp) 78 (223). Under conditions of cellular 
stress, the amount of misfolded and unfolded proteins in the ER rises, which activates the 
unfolded protein response (UPR), an indicator of ER stress (224, 225). At least three different 
signalling pathways are activated by ER stress: the Protein kinase-like Endoplasmic 
Reticulum Kinase (PERK), the endoribunuclease/kinase inositol-requiring (IRE) 1α, and the 
activating transcription factor (ATF) 6 (226). Under normal conditions, these sensors are 
located in the ER membrane and held in an inactive state by bound chaperones. When 
unfolded proteins aggregate in the ER, the chaperones are sequestered into the ER lumen, 
which allows activation of the ER stress sensors. Activation of the UPR signalling pathways 
leads to a reduction in total protein translation, and transcription factors such as C/EBP-
homologous protein (CHOP) and x-box binding protein (XBP) 1 are activated, which increase 
expression of chaperones and enzymes required for protein folding (227). If ER stress 
persists, the UPR can induce apoptosis (227). ER stress can be caused by viral infections, 
protein misfolding diseases such as Huntingtons, toxic chemical agents, and as previously 
mentioned, by obesity (203). Mechanistical insight into how obesity induces ER stress is 
limited, although oversupply of amino acids, glucose and lipids as well as hyperinsulinemia 
are known to stimulate transcription and translation, which might overwhelm the protein 
folding capacity of the ER (228-230). Tissues such as liver, pancreas and WAT, which are 
crucial for lipid and glucose metabolism and are directly affected by rising glucose and lipid 
levels, have repeatedly been shown to show high levels of ER stress under obese conditions 
(202, 203, 223). Importantly, hepatic ER stress was shown to induce insulin resistance by 
activation of JNK and NFκB signalling (201, 203, 223, 231, 232).  
 Ozcan and colleagues reported, that partial ablation of neuronal UPR signalling 
cascades leads to severe leptin resistance and in turn, icv injection of chemical chaperones 
ameliorates diet-induced obesity (233). In line with this, NFκB signalling is activated by 
neuronal ER stress, whereas ablation of NFκB signalling also reduces neuronal ER stress by 
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unknown mechanisms (184). Taken together, neuronal ER stress induces insulin and leptin 
resistance, although the specific signalling cascades both upstream as well as downstream of 
ER stress in the CNS are poorly understood. 
 
1.14 Objectives 
 The first aim of this study was to analyse the role of PI3K downstream signalling in a 
defined neuronal population critical for energy homeostasis (POMC neurons) under both ND 
and HFD conditions. The second aim of this study was to understand the role of inflammatory 
mediators such as cytokines and lipids partially acting through the stress kinase JNK1 on 
PI3K signalling in the hypothalamus as well as on a pan-neuronal level.  
 
Besides wild type C57BL/6 mice, the following mutant mouse models were used in this 
study: 
 
- Mice with POMC cell-specific PDK1 deletion 
- Mice with POMC cell-specific PDK1 deletion and overexpression of FOXO1Δ256 
- Mice with Nestin cell-specific JNK1 deletion 
 
 
 
 
 
 
 
 
 
                                                                                                                   Materials & Methods 
   33
 
2 Materials and Methods 
 
2.1 Chemicals and Biologicals 
Size markers for agarose gel electrophoresis (Gene Ruler DNA ladder mix) and for SDS-
PAGE (Prestained protein ladder Mix) were purchased from Fermentas, St. Leon-Rot, 
Germany. For polymerase chain reactions, RedTaq polymerase (Sigma-Aldrich, Seelze, 
Germany) or DreamTaq (Fermentas, St. Leon-Rot, Germany) were used. Chemicals and 
enzymes used in this work are listed in Table 1 and 2, respectively.  
 
 
Table 1: Chemicals 
β-Mercaptoethanol (β-M) AppliChem, Darmstadt, Germany 
ε-aminocaproic acid Sigma-Aldrich, Seelze, Germany 
0.9% saline, sterile Delta Select, Pfullingen, Germany 
2,2,2-Tribromethanol (Avertin) Sigma-Aldrich, Seelze, Germany 
Acrylamide Roth, Karlsruhe, Germany 
Agarose (Ultra Pure) Invitrogen, Karlsruhe, Germany 
Ammoniumpersulfat Sigma-Aldrich, Seelze, Germany 
Aprotinin Sigma-Aldrich, Seelze, Germany 
Avidin Biotin Complex – Vectastain Elite Vector, Burlingame, USA 
Bacillol Bode Chemie, Hamburg, Germany 
Benzamidine Sigma-Aldrich, Seelze, Germany 
Bovine serum albumin (BSA) Sigma-Aldrich, Seelze, Germany 
Bromphenol blue Marck, Darmstadt, Germany 
Calcium chloride Merck, Darmstadt, Germany 
Chloroform Merck, Darmstadt, Germany 
Diaminobenzidin (DAB) Dako, Denmark 
Dimethylsulfoxide (DMSO) Merck, Darmstadt, Germany 
di-Natriumhydrogenphosphat Merck, Darmstadt, Germany 
Enhanced chemiluminescence (ECL) kit Perbio Science, Bonn, Germany 
Ethanol, absolute Applichem, Darmstadt, Germany 
Ethidium bromide Sigma-Aldrich, Seelze, Germany 
                                                                                                                   Materials & Methods 
   34
 
Ethylendiamide tatraacetate (EDTA) Applichem, Darmstadt, Germany 
Forene (Isoflurane) Abbot GmbH, Wiesbaden, Germany 
Glucose 20%, sterile DeltaSelect, Pfullingen, Germany 
Glycerol Serva, Heidelberg, Germany 
HEPES Applichem, Darmstadt, Germany 
Hydrochlorid acid (37%) KMF Laborchemie, Lohmar, Germany 
Hydrogen peroxide Sigma-Aldrich, Seelze, Germany 
Insulin (human) Novo Nordisk, Basvaerd, Denmark 
Insulin (porcine) Sigma-Aldrich, Seelze, Germany 
Isopropanol Roth, Karlsruhe, Germany 
Kaisers Glycerin Gelatine Merck, Darmstadt, Germany 
Magnesium chloride Merck, Darmstadt, Germany 
Methanol Roth, Karlsruhe, Germany 
Nitrogen (liquid) Linde, Pullach, Germany 
Octenisept Schülke & Mayr, Norderstedt, Germany 
Paraformaldehyde (PFA) Fluka, Sigma-Aldrich, Seelze, Germany 
Phenylmethylsulfonylfluoride (PMSF) Sigma-Aldrich, Seelze, Germany 
Phosphate buffered saline (PBS) Gibco, Eggenstein, Germany 
Potassium hydroxide Merck, Darmstadt, Germany 
Sodium chloride Applichem, Darmstadt, Germany 
Sodium dodecyl sulfate (SDS) Applichem, Darmstadt, Germany 
Sodium fluoride Merck, Darmstadt, Germany 
Sodium hydroxide Applichem, Darmstadt, Germany 
Sodium orthovanadate Sigma-Aldrich, Seelze, Germany 
Sodium pyruvate (cell culture tested) Sigma-Aldrich, Seelze, Germany 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich, Seelze, Germany 
Tissue freezing medium Jung, Heidelberg, Germany 
Tramadolhydrochlorid (Tramal) Grünenthal, Aachen, Germany 
Trishydroxymethylaminomethane (Tris) AppliChem, Darmstadt, Germany 
Triton X-100 Applichem , Darmstadt, Germany 
Vectashield Mounting Medium with DAPI Vector, Burlingame, USA 
Western Blocking Reagent Roche, Mannheim, Germany 
Zinc sulphate Fluka, Sigma-Aldrich, Seelze, Germany 
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Table 2: Enzymes 
DNase, RNase-free Promega, Madison, WI, USA 
Euroscript Reverse Transcriptase Eurogentec, Seraing, Belgium 
Proteinase K Roche, Basel, Switzerland 
RedTaq DNA Polymerase Sigma-Aldrich, Seelze, Germany 
RNase Inhibitor Eurogentec, Seraing, Belgium 
 
 
2.2 Molecular Biology 
 Standard methods of molecular biology were performed according to protocols 
described by J. Sambrook, unless otherwise stated (234). 
 
2.2.1 Isolation of genomic DNA 
Mouse tail biopsies were digested overnight in lysis buffer (100mM Tris pH 8.5, 5mM 
EDTA, 0.2% (w/v) SDS, 0.2M NaCl, 500mg/ml Proteinase K) in a thermomixer (Eppendorf,  
Hamburg, Germany). DNA was precipitated by adding an equivalent volume of 2-Propanol  
(100%). After washing with 70% (v/v) ethanol and subsequent centrifugation, the DNA pellet  
was dried and redissolved in double distilled water (ddH2O).  
 
2.2.2 Quantification of nucleic acids 
 DNA and RNA concentrations were quantified by measuring the sample absorption at 
260nm and 280nm with a NanoDrop ND-1000 UV-Vis Spectrophotomoter (Peqlab, Erlangen,  
Germany). An optical density of 1 corresponds to approximately 50µg/ml of double stranded 
DNA and to 38µg/ml of RNA. A ratio greater than 2 of absorptions at 260nm (DNA/RNA) 
divided by the absorption at 280nm (protein) was used as an index of purity of DNA/RNA. 
 
2.2.3 Polymerase chain reaction 
 PCR was used to detect loxP flanked exons and various transgenes with primers 
described in table 3. Reactions were performed in a Thermocycler iCycler PCR machine 
(BioRad, München, Germany) or in a Peltier Therman Cycler PTC-200 (MJ Research, 
Waltham, USA). All amplifications were performed in a total reaction volume of 30µl, 
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containing a minimum of 50ng template DNA, 25pmol of each primer, 25µM dNTP mix, 
polymerase buffer and 1.1 unit of polymerase. Standard PCR programs started with 5min of 
denaturation at 95°C, followed by 35 cycles consisting of denaturation at 95°C for 45 seconds 
(sec), annealing at oligonucleotide-specific temperatures for 30sec and elongation at 72°C for 
30 sec, and a final elongation step at 72°C for 7min.  
 
Table 3: Primer sequences 
All primer sequences are displayed in 5´Æ3´ order. Primer orientation is designated "sense" 
when coinciding with transcriptional direction. All primers were purchased from Eurogentec, 
Belgium. 
Primer Sequence Tannealing °C direction 
POMC-Cre 1 TGGCTCAATGTCCTTCCT GG 55 sense 
POMC-Cre 2 CACATAAGCTGCATCGTTAAG 55 antisense
POMC-Cre 3 CACATAAGCTGCATCGTTAAG 55 antisense
PDK1 1 ATCCCAAGTTACTGAGTTGTGTTGGAAG 55 sense 
PDK1 2 TGTGGACAAACAGCAATGAACATACACGC 55 antisense
PDK1 Δ CAGTTCATCATTGCAAGAGTC 54 sense 
CAGS 1 AAAGTCGCTCTGAGTTGTTATC 55 sense 
CAGS 2 GATATGAAGTACTGGGCTCTT 55 antisense
CAGS 3 TGTCGCAAATTAACTGTGAATC 55 antisense
LACZ 1 ATC CTC TGC ATG GTC AGG TC 60 sense 
LACZ 2 CGT GGC CTG ATT CAT TCC 60 antisense
GFP 1 CTG GTC GAG CTG GAC GGC GAC G 62 sense 
GFP 2 CAG GAA CTC CAG CAG GAC CAT G 62 antisense
Nestin-Cre 1 CGC TTC CGC TGG GTC ACT GTC G 58 sense 
Nestin-Cre 2 TCG TTG CAT CGA CCG GTA ATG CAG GC 58 antisense
JNK1 1 ACATGTACCATGTACTGACCTAAG 54 sense 
JNK1 2 CATTACTCTA CTCACTATAG TAACA 54 antisense
JNK1 Δ GATATCAGTA TATGTCCTTA TAG 54 antisense
 
2.2.4 RNA extraction, RT-PCR and Quantitative Real-Time PCR 
 Tissues were homogenized using an Ultra Turrax homogenizer (IKA, Staufen, 
Germany). RNA was extracted using the Qiagen RNeasy Kit (Qiagen, Hilden, Germany). 
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When exon-spanning probes were not available to quantify RNA expression of target genes, 
on-column DNA digestion was performed (RNAse-free DNAse, Qiagen, Hilden, Germany). 
200ng RNA was reverse-transcribed into cDNA using the Eurogentec RT KIT (Eurogentec, 
Belgium). For quantitative Real-Time PCR, 100ng cDNA was amplified using Taqman 
Universal PCR-mastermix, NO AmpERASE  UNG with Taqman assay on demand kits 
(Applied Biosystems, Foster City, USA) (see Table 4) with the exception of genes for which 
no commercial probes were available. For these genes, custom probes were designed as 
depicted in Table 5. Relative expression of genes was adjusted for total RNA content by 
glucuronidase β (GUSB) and hypoxyanthine guanine phosphoriboysl transferase (HPRT) 1 
RNA quantitiatve Real-Time PCR. Real-Time PCR analysis was performed on an ABI-
PRISM 7700 Sequence detector (Applied Biosystems, Foster City, USA). Assays were linear 
over 4 orders of magnitude.  
 
Table 4: Real-Time analysis probes 
POMC Mm00435874_m1 Bax Mm00432050_m1 
CART Mm00489086_m1 Bak Mm00432045_m1 
AgRP Mm00475829_g1 Zac1 Mm00494250_m1 
NPY Mm00445771_m1 GHRH Mm00439100_m1 
CRH Mm01293920_s1 Somatostatin Mm00436671_m1 
TRH Mm01963590_s1 GHRHR Mm01326479_m1 
BDNF Mm01334042_m1 TRHR Mm00443262_m1 
GUSB Mm00446953_m1 PIT-1 Mm00476852_m1 
HPRT Mm03024075_m1 Orexin Mm01185778_m1 
MCH Mm01242886_g1 LPL Mm00434770_m1 
HSL Mm00495359_m1 UCP1 Mm00494069_m1 
UCP2 Mm00627599_m1 UCP3 Mm00494077_m1 
TNFα Mm99999068_m1 IL6 Mm99999064_m1 
F4/80 Mm00802530_m1 MCP1 Mm99999056_m1 
MAC2 Mm00802901_m1 LysM Mm00769128_m1 
IL10 Mm00439614_m1 PPARγ Mm00440945_m1 
JNK2 Mm00444231_m1 JNK3 Mm00436518_m1 
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Table 5: Custom Real-Time analysis probes 
target 
RNA 
5` primer 3` primer probe 
GH 
(custom) 
GCCCTTGTCCAGTC
TGTTTTC 
GATGGTCTCTGAGAA
GCAGAAAG 
GTTCGAGCGTGCCTAC
ATTCC 
POMC 
(custom) 
GACACGTGGAAGA
TGCCGAG 
CAGCGAGAGGTCGA
GTTTGC 
CAACCTGCTGGCTTGC
ATCCGG 
JNK1 
(custom) 
ATTGGAGATTCTAC
ATTCACAGTCCTA 
CATTCTGAAATGGCC
GGCT 
AGTGTGTGCAGCTTAT
GATGCC 
 
2.3 Cell Biology 
2.3.1 Histological analysis and immunohistochemistry 
 POMC-Cre+/- were mated with RosaArte1 mice or Z/EG mice to generate lacZΔPOMC 
and GFPΔPOMC mice which served as controls for the immunohistochemistry studies (168). 
PDK1ΔPOMC mice were mated with RosaArte1 mice to generate lacZ:PDK1ΔPOMC mice which 
lack PDK1 in POMC-expressing cells but in these cells express lacZ.  
 To determine efficiency of PDK1 ablation in PDK1ΔPOMC mice, PDK1/lacZ double 
stainings were performed. LacZ control and lacZ KO reporter mice were perfused 
transcardially with physiologic saline solution, frozen in tissue freezing medium (Jung, Leica 
Instruments, Germany), and sectioned on a cryostat. Tissues were stained with goat anti-β-
galactosidase (4600-1409, Biogenesis) and rabbit anti-PDK1 (#1624-1, Epitomics, 
Burlingame, CA, USA), and double-fluorescence immunostaining was performed using 
donkey serum for blocking (#S30, Chemicon, Temecula, CA, USA), donkey anti-goat FITC-
coupled secondary antibody (#sc-2024, Santa Cruz Biotech., Santa Cruz, CA, USA) and 
donkey anti-rabbit secondary MFP antibody (#a2207, MoBiTec, Goettingen, Germany) as 
previously described (151). 
 For GFP stainings, mice were perfused with saline solution followed by 4% 
paraformaldehyde (PFA) in 0.1 M phosphate-buffered saline (PBS; pH 7.4). Hypothalami and 
pituitaries were dissected, postfixed in 4% PFA at 4°C, transferred to 20% sucrose for 6 hr, 
and frozen in tissue freezing medium. Then, 25 µm thick free-floating coronal sections were 
cut through the ARC using a freezing microtome (Leica, Germany). The sections were 
collected in PBS/azide (pH 7.4) and washed extensively to remove cryoprotectant. The 
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sections were stained as previously described, using rabbit anti-GFP antibody at a 1:10000 
dilution (#A6455 from Invitrogen/Molecular Probes, Karlsruhe, Germany) (235). 
 For pituitary stainings of ACTH, GH or TSHβ, sections were attained as described 
above, and stainings were performed using the ACTH and TSHβ antibody kindly provided by 
A.F. Parlow from the National Hormone and Peptide Program or GH antibody (#A0570) from 
DAKO, USA.  
 Slides were viewed through a Zeiss Axioskop equipped with a Zeiss AxioCam for 
acquisition of digital images using Spot Advanced 3.0.3 software or through a digital camera 
attached to a binocular (for low magnifications). Please note that 25% less slides from 4 week 
old GFP reporter mice compared to 12 week old GFP reporter mice were counted, therefore 
absolute numbers of 4 and 12 week old mice cannot be compared. 
 
2.4 Biochemistry 
2.4.1 Enzyme-linked Immunosorbent Assay (ELISA) 
 Serum insulin, leptin, plasma corticosterone, growth hormone (GH), insulin-like 
growth factor (IGF) I, free thyroxin 3 (T3) and adiponectin were measured by ELISA using 
mouse standards according to the manufacturer’s guidelines (Mouse Leptin ELISA, #90030, 
Crystal Chem., Downers Grove, IL, USA; Rat Insulin ELISA, #INSKR020, Crystal Chem., 
Downers Grove, IL, USA; Corticosterone EIA Kit, #900-097, Assay Designs, Ann Arbor, MI, 
USA; Mouse Growth hormone ELISA, #EZRMGH-45K, Millipore, St. Charles, MI, USA; 
Mouse IGF-1 ELISA, #MG100, R&D Systems, Minneapolis, MN, USA; free T3 ELISA, 
Alpha Diagnostics International. Inc, San Antionio, Texas, USA; mouse adiponectin, 
#MRP300, R&D Systems). 
 
2.4.2 Protein extraction 
 Tissues were snap-frozen in liquid nitrogen until protein extraction. Tissues were 
homogenized in lysis buffer (50 mM HEPES (ph 7.4), 1% Triton X-100, 0.1 M NaF, 10 mM 
EDTA, 50 mM NaCl, 0.1% SDS, proteinase and phosphatase inhibitor cocktail tablets 
(Roche,  Mannheim, Germany)). Lysates were cleared by centrifugation for 45 min at 
13000rpm. Protein concentration of the resulting supernatant was analysed using a NanoDrop 
ND-1000 UV-Vis spectrophotometer (Peqlab, Erlangen, Germany). Protein supernatant was 
diluted with 4xSDS sample buffer (125 mM Tris-HCl (ph6.8), 5% SDS, 43.5% glycerol, 100 
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mM DTT, 0.02% bromophenol blue) to an end concentration of 10mg/ml protein. Before 
loading of samples onto a Western blot gel, proteins were boiled at 95°C for 5 min. 
 
2.4.3 Western Blotting 
 Samples were separated on 10% (v/v) SDS polyacrylamide gels and blotted onto 
PVDF membranes (Bio-Rad, München, Germany). Membranes were blocked with 1% 
blocking reagent (Roche, Mannheim, Germany) for 1h at RT. Subsequently, primary 
antibodies (Table 5) diluted in 0.5% blocking reagent at a concentration of 1:1000 were 
applied overnight at 4°C. After 4x washing with 1% TBS-Tween (TBS-T) for 10min each, 
secondary antibody was applied for 1h at RT.  After a repeat wash step, membranes were 
incubated for 1min in Pierce ECL Western Blocking Substrate (Perbio Science, Bonn, 
Germany) and exposed to chemiluminescence films (Amersham, Braunschweig, Germany). 
Films were developed in an automatic developer (Kodak, Germany).  
 
Table 6: Western Blotting antibodies 
Antibody Catalogue # Company 
β-actin A5441 Sigma Aldrich 
PDK1 #1624-1 Epitomics, Burlingame, CA, USA 
IR-β sc-711 Santa Cruz, San Diego, CA, USA 
pS473-AKT 4058 Cell Signalling 
pan-AKT 9272 Cell Signalling 
JNK1/3 sc-474 Santa Cruz 
phospho-S63-c-jun kit #9810 Cell Signalling 
 
2.4.4 C-jun N-terminal kinase assay 
 SAPK/JNK assays were performed following the manufacturer’s guidelines (#9810, 
Cell Signalling). Tissues were homogenized in assay buffer, incubated with c-jun fusion 
protein overnight and after washing, incubated with kinase buffer containing ATP. After the 
reaction was stopped, samples were loaded onto a 10% polyacrilamide gel. Western blots 
were performed using the phospho-c-jun antibody supplied in the kit. JNK assays were 
performed with the kind help of Dr. Jan Mauer, Institute for Genetics, University of Cologne. 
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2.4.5 Hepatic lipid content analysis 
 Samples of mouse liver tissue (50 to 150 mg, n = 4) were homogenized with the 
Homogenisator Precellys 24 (Peqlab, Erlangen, Germany) in 1 ml of water at 6.500 rpm for 
30 sec. The protein content of the homogenate was routinely determined using bicinchoninic 
acid. After addition of 4 ml of methanol and 2 ml of chloroform, lipids were extracted for 24 
h at 37 °C. The liquid phase was separated by filtration, and the insoluble tissue residues were 
further extracted for 24 h at 37 °C in 6 ml of methanol/chloroform 1:1 (v/v) and finally in 6 
ml of methanol/chloroform 1:2 (v/v). The extracts were pooled, and the solvent was 
evaporated in a stream of nitrogen. The residues were purified using a modification of the 
Bligh-Dyer procedure as previously described (236). Lipids were applied to 20 × 10 cm high 
performance thin layer chromatography (HPTLC) Silica Gel 60 plates (Merck, Darmstadt, 
Germany), which were pre-washed twice with chloroform/methanol 1:1 (v/v) and air-dried for 
30 min. For quantification of triacylglycerols and cholesteryl esters, each lane of the TLC 
plate was loaded with the equivalent of 50 µg and 1 mg wet weight of liver tissue, 
respectively. The TLC solvent system used was hexane/toluene 1:1 (v/v), followed by 
hexane/diethyl ether/glacial acetic acid 80:20:1 (v/v). For quantification of cholesterol, 
diacylglycerols and free fatty acids, the equivalent of 2.5 mg of liver tissue was applied to 20 
× 20 cm TLC plates, which were developed in hexane/ diethyl ether/ formic acid 30:50:1 
(v/v/v). For quantitative analytical TLC determination, increasing amounts of standard lipids 
(Sigma-Aldrich, Taufkirchen, Germany) were applied to the TLC plates in addition to the 
lipid samples. For detection of lipid bands, the TLC plates were sprayed with a phosphoric 
acid/copper sulfate reagent (15.6 g of CuSO4(H2O)5 and 9.4 ml of H3PO4 (85 %, w/v) in 100 
ml of water) and charred at 180 °C for 10 min. Lipid bands were then quantified by 
densitometry using the TLC-Scanner 3 (CAMAG, Berlin, Germany) at a wavelength of 595 
nm. Lipid analysis was performed by and with Dr. Susanne Brodesser, CECAD, Lipidomics 
Facility. 
 
2.5 Mouse experiments 
 General animal handling was performed as described previously (237). 
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2.5.1 Animal care 
 Care of all animals was within institutional animal care committee guidelines. All 
animal procedures were conducted in compliance with protocols and approved by local 
government authorities (Bezirksregierung Köln, Cologne, Germany) and were in accordance 
with NIH guidelines. Mice were housed in groups of 3–5 at 22–24°C using a 12-hour light / 
12-hour dark cycle. Animals were either fed normal chow diet (Teklad Global Rodent 2018; 
Harlan) containing 53.5% carbohydrates, 18.5% protein, and 5.5% fat (12% of calories from 
fat) or a high-fat diet  (HFD; C1057; Altromin) containing 32.7% carbohydrates, 20% protein, 
and 35.5% fat (55.2% of calories from fat). Animals had ad libitum access to water at all 
times, and food was only withdrawn if required for an experiment. Body weight was 
measured once a week; body length (naso-anal length) was measured before sacrifice. Mice 
were sacrificed by lethal CO2 anaesthesia. 
 
2.5.2 Mice 
 POMC-Cre mice (152) were mated with PDK1flΔneo/flΔneo (80) and breeding colonies 
were maintained by mating male POMC-Cre-PDK1flΔneo/flΔneo (PDK1ΔPOMC) mice with female 
PDK1flΔneo/flΔneo mice. PDK1fl∆neo/fl∆neo mice were backcrossed three times onto a C57bl/6 
background before crossing with POMC-Cre mice.  
 For analysis of the role of FOXO1-dependent signalling in POMC cells, a mouse was 
generated with Cre-inducible expression of a dominant-negative FOXO1 mutant protein, 
which lacks the transactivation and the NLS domain (FOXO1Δ256) (89, 238). In this mouse 
line, the expression of the FOXO1Δ256 mutant and IRES-GFP from the ubiquitously expressed 
ROSA26 locus is inhibited by a loxP-site flanked Stop-cassette (238). This mouse was 
originally generated and kindly provided by Marianne Ernst and Dr. F. Thomas Wunderlich 
in the laboratory of Prof. Dr. Jens C. Brüning in the Institute for Genetics, University of 
Cologne, Germany (238). All FOXO1Δ256:PDK1ΔPOMC mice were heterozygous for the 
FOXO1Δ256 transgene (238). 
 Nestin-Cre mice (239) were mated with JNK1fl/fl mice (generated by Dr. F. Thomas 
Wunderlich and Prof. Dr. Jens C. Brüning in the Institute for Genetics, Unversity of Cologne) 
and breeding colonies were maintained by mating male Nestin-Cre-JNK1fl/fl (JNK1ΔNES) with 
female JNK1fl/fl mice. JNK1fl/wt mice were backcrossed on a C57/bl6 background for three 
additional times before being intercrossed to generate JNK1fl/fl mice.  
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 The backgrounds of experimental animals were unchanged throughout all 
experiments. Littermates were used for analysis at all times except for reporter mouse studies. 
Mice were genotyped by PCR using genomic DNA isolated from tail tips. Germline deletion 
was excluded using primers designed to detected deleted alleles in the tail tip. Additionally, 
tissues not expressing Cre were used to examine mRNA expression of the various loxP-
flanked genes through Real-Time PCR analysis.  
 
2.5.3 Blood collection and determination of glucose levels 
 Tail bleeding was performed as described before (237). Blood glucose values were 
determined from whole venous blood using an automatic glucose monitor (GlucoMen; A. 
Menarini Diagnostics, Florence, Italy). For collection of plasma, EDTA (1.6 mg/1ml serum) 
was added to prevent clotting. Determination of blood glucose levels and collection of blood 
samples from control and various conditional knockout mice were performed side-by-side in 
the morning to avoid intra-group deviations due to circadian variations. 
 
2.5.4 Food intake and indirect calorimetry 
 Daily food intake was calculated as the average intake of chow from custom made 
food racks within the time stated. Mice were acclimated to the food intake settings for at least 
five days. Weight of the racks was determined every day. Calorimetry measurements were 
performed in a PhenoMaster System (TSE systems, Bad Homburg, Germany), which allows 
measurement of metabolic performance and activity-monitoring by an infrared light-beam 
frame. Mice were placed at room temperature (22 °C–24 °C) in 7.1-l chambers of the 
PhenoMaster open circuit calorimetry. Mice were allowed to adapt to the chambers for at least 
24h. Food and water were provided ad libitum in the appropriate devices and measured by the 
build-in automated instruments. Locomotor activity and parameters of indirect calorimetry 
were measured for at least the following 48 hr. Presented data are average values obtained in 
these recordings. 
 
2.5.5 Glucose, insulin and pyruvate tolerance test 
 For glucose tolerance tests (GTT), mice were fasted overnight for 16h. After 
determination of fasted blood glucose levels, each animal received an intraperitoneal injection 
of 20% glucose solution (10ml/kg body weight). Blood glucose was determined 15, 30, 60, 
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and 120min after injection. For insulin tolerance tests (ITT), each random fed animal received 
an intraperitoneal injection of 0,75U/ml insulin solution (0,75U/kg body weight) after 
determination of random fed blood glucose concentration. For pyruvate tolerance tests (PTT), 
mice were fasted for 20h, followed by i.p. injection of 2g/kg sodium pyruvate (Sigma-
Aldrich) dissolved in 0.9% saline solution. Blood glucose was determined 15, 30, 60 and 
120min after injection, and blood glucose concentrations relative to starting blood glucose 
levels were calculated. 
 
2.5.6 Analysis of body composition 
 Body fat content was measured in vivo by nuclear magnetic resonance using a 
minispec mq7.5 (Bruker Optik, Ettlingen, Germany). Radiofrequency pulse sequences are 
transmitted into mouse tissue, which are retransmitted by hydrogen atoms in the tissue, the 
signals of which are detected by the minispec. Amplitude and duration of these signals are 
related to properties of the material. 
 
2.5.7 Restraint stress 
 Mice were handled at least weekly after weaning. Before the restraint, blood was taken 
from the tail vein for determination of basal plasma corticosterone levels. Directly after that, 
mice were subjected to 60 minutes of restraint in a plastic tube with openings for air supply. 
Directly after the restraint, blood was collected from the tail vein into EDTA-containing tubes 
for determination of stressed plasma corticosterone levels (from plasma samples). 
 
2.5.8 Intracerebroventricular indwelling catheter implantation 
For icv cannula implantation, 10-week-old male C57BL/6 (Charles River 
Laboratories) mice were anesthetized by intraperitoneal injection of Avertin (650 mg/kg) 
(2,2,2-tribromoethanol; Sigma) and placed in a stereotactic device (Stoelting; Foehr Medical 
Instruments GmbH, Germany). A sterile osmotic pump connector cannula (Bilaney 
Consultants) was implanted into the left lateral brain ventricle (–0.2 mm anterior and 1.0 mm 
lateral relative to Bregma and 2.3 mm below the surface of the skull). The support plate of the 
catheter was attached to the skull with Super Glue (Super Glue Corp.). The catheter was 
prefilled with 0.9% saline and connected to a sealed microrenathane catheter (MRE-025; 
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Braintree Scientific Inc.). After 5 days of recovery, mice were fasted overnight and the sealed 
microrenathane catheter was removed. TNF-α (Sigma-Aldrich) dissolved in aCSF or vehicle 
(aCSF) was injected in a volume of 2µl according to the respective experimental set-up. The 
catheter was subsequently sealed to avoid backflow. Injections were performed in isoflurane 
anesthesia. Mice were killed after 24h.  
 For experiments with multiple icv injections into the same mouse, male JNK1fl/fl and 
JNK1ΔNES mice were anesthetized by intraperitoneal injection of avertin (2,2,2-
tribromoethanol, 0.2 ml/g). Scalp fur was shaved and prepared using sterile techniques and 
the mice were then placed into a stereotaxic device (Stoelting; Foehr Medical Instruments 
GmbH, Germany) with lambda and bregma at the same vertical coordinate. A small midline 
incision was made over the dorsal scalp to provide access to the cranium and the cranial 
surface was cleaned by swabbing with hydrogen peroxide and allowed to dry. The lateral 
ventricle was targeted using coordinates located using a Brain Atlas (coordinates were bregma 
1.0mm lateral, 0.2mm caudal, and 2.0mm ventral). A 5 mm2 skull window was outlined with 
a fine dremel bit and removed with forceps; the sagittal sinus was displaced laterally prior to 
lowering a 26-gauge stainless steel cannula (Plastics One, Roanoke, VA) such that the 
cannula tip was 4.8 mm below bregma. Dental acrylic was used to secure the cannula to the 
skull. After 1 week recovery, mice were icv injected with insulin, leptin or aCSF according to 
the experimental paradigm, and food intake and body weight was measured before and 24h 
later.  
 For icv insulin signalling experiments, mice were fasted for 48h, injected with aCSF 
or insulin, sacrificed 20min later and tissues extracted as necessary. 
 
2.5.9 Intraperitoneal leptin sensitivity tests 
 For i.p. leptin sensitivity tests, vehicle (0.9% NaCl) or leptin at a dose of 2 mg/kg was 
injected twice daily over a period of 3 consecutive days. Body weight and food intake was 
monitored twice daily.  
 
2.5.10 Implantation of osmotic minipumps 
 To investigate the effect of corticosterone restoration in the hypocorticosteronemic 
PDK1ΔPOMC mice, osmotic minipumps filled with corticosterone were implanted. Before 
surgery, dexamethasone (5 mg/kg BW; Sigma-Aldrich)) was injected i.p. to prevent death as a 
consequence of stress arising from surgery in PDK1ΔPOMC mice. Osmotic minipumps (Model 
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2004, Alzet, California, USA) pre-filled with 10µg/µl corticosterone dissolved in PEG400 
(Sigma-Aldrich) were implanted in anaesthetized mice according to the manufacturers 
instructions. Blood was taken every week between 2 and 4 pm. Mice which did not show a 
significant increase in plasma corticosterone were dismissed from the study. 
 
2.5.11 Behavioural analysis 
To control for behavioural differences between control and JNK1∆NES mice, several 
experimental paradigms were analysed. To examine locomotor efficacy, Rotarod analysis was 
performed. Control and JNK1∆NES mice were mounted on the Rotarod, and total time on the 
accelerating rotating rod until mouse fell off was measured. To analyze anxiety, the zero maze 
paradigm was chosen. Control and JNK1∆NES mice were put on the zero maze, and the time in 
which the mouse stayed in the closed part of the maze was tracked by an automatic visual 
system. Additionally, open field analysis of control and JNK1∆NES mice was performed. 
Control and JNK1∆NES mice were put into the open field, and the time in which the mouse 
stayed close to the wall and total distance travelled was tracked by an automatic computer-
based system. To gain insight into potentially impaired spatial memory, Morris water maze 
analysis was performed. Control and JNK1∆NES mice were trained daily for 4 days to 
memorize the location of submerged platform in a water pool using several local markers, and 
the time taken by each mouse to find the platform was measured by an automatic, software 
based system. On the fifth day of the Morris water maze analysis, the platform was removed 
from the pool, and the time the mouse swam in the quadrant in which the platform had been 
was automatically measured by an automatic, software based system. All experimental setups 
were purchased from TSE Systems, Bad Homburg, Germany, and the experimental analysis 
was performed by and with the help of Dr. Hella Brönneke, Cluster of Excellence in aging-
associated diseases (CECAD), University of Cologne, Germany. 
 
2.6 Cell culture 
 GH4C1 cells (240) cells were cultivated in 5% CO2 at 37°C in DMEM with 10% FCS 
and  Penicillin/Streptomycin. 1x106 cells per 6cm well were fasted for 6h, followed by 16h of 
stimulation with either control, SP600125, LY294002 or PD98059 (Sigma-Aldrich). All 
inhibitors were used at a final concentration of 10µM, and were prepared on the day of the 
experiment. DMSO was present in all wells at a final concentration of 0.1%. The experiments 
were performed in triplicates, and three independent experiments were analysed with rat 
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specific Real-Time probes for TRHR (Rn00564882_m1) and GUSB (Rn00566655_m1) as a 
housekeeping gene (Applied Biosystems).  
 
2.7 Computer analysis 
2.7.1 Densitometrical analysis 
 Western Blot bands were measured in intensity per mm2 using the Quantitiy One 
Software (Bio-Rad, München, Germany). After background subtraction, each sample was 
normalized to an internal loading control such as the unphosphorylated protein, IRβ or β-actin 
expression.  Average protein expression of control mice was set to 1 or 100% and compared 
to expression of conditional knockout mice unless stated otherwise.   
 
2.7.2 Statistical methods 
 Data were analysed for statistical significance by two-tailed unpaired Student’s t test 
unless indicated otherwise.  P values below 0.05 were considered significant. All displayed 
values are means +/- SEM. *p<0.05; **p<0.01; ***p<0.001.  
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3 Results 
 
3.1 Generation of POMC cell-specific PDK1 knockout mice 
To address the effect of kinase signalling downstream of PI3K on energy homeostasis 
and stress response in vivo, we generated mice lacking 3-phosphoinositide-dependent protein 
kinase-1 (PDK1) selectively in POMC-expressing cells (PDK1ΔPOMC) using Cre/loxP-
mediated recombination. To this end, mice expressing a Cre recombinase under control of the 
POMC-promoter (152, 241) were crossed with mice carrying a loxP-flanked PDK1 gene 
(PDK1 flΔneo/flΔneo) (Figure 5) (80). 
Exon 3
A
B
Exon 2
>45kb POMC 5`
sequences
Cre
ATG STOP
>70kb POMC 3`
sequences
ATG
Exon 4
PDK1
Exon 1
 
Figure 5: Targeted genomic loci in PDK1flΔneo/flΔneo and POMC-Cre mice.  
A) In PDK1flΔneo/flΔneo mice, exon 3 and 4 are flanked by loxP sequences. Cre-mediated excision of these exons 
will induce a frame-shift, inhibiting translation of the PH and the kinase domain and leading to a premature stop 
of translation. B) POMC-Cre mice are carriers of a POMC bacterial artificial chromosome (BAC) in which a Cre 
expression cassette was inserted into the translational initiaton site (ATG) of POMC exon 2.  
 
In PDK1flΔneo/flΔneo mice, which served as controls, exons 3 and 4 are flanked by loxP 
sites which does not impair transcription of the PDK1 gene or translation of PDK1 mRNA 
(80, 238, 242). In littermates which inherit the POMC-Cre transgene, exons 3 and 4 are 
removed in all POMC expressing cells, leading to a frameshift mutation and thus selective 
inactivation of the PDK1 gene only in POMC cells (PDK1ΔPOMC mice) ( (80, 238).  
 
To analyze cell-type specific inactivation of PDK1, Cre-mediated recombination was 
visualized by crossing POMC-Cre mice and PDK1ΔPOMC mice to a reporter mouse strain 
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expressing the β-galactosidase gene (lacZ) under control of the ubiquitously expressed 
ROSA26 promoter only after Cre-mediated removal of a floxed hygromycin resistance gene 
(243). Analysis of lacZ immunoreactivity in lacZΔPOMC mice revealed a pattern of expression 
in the hypothalamus in agreement with reported localisation of Cre and POMC expression in 
POMC-Cre mice (152).  
Double immunostaining for PDK1 and lacZ revealed expression of PDK1 in 
approximately 70% of lacZ-expressing cells. Consistently, PDK1 expression was reduced to 
less than 10% of lacZ-positive hypothalamic neurons in lacZ:PDK1ΔPOMC reporter mice 
(Figure 6).  
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Figure 6: Ablation of the PDK1 protein in POMC neurons.  
A) Detection of PDK1 in POMC neurons by immunohistochemistry. Using lacZΔPOMC and lacZ:PDK1ΔPOMC 
reporter mice, co-immunohistochemistry for β-galactosidase and PDK1 was performed, and the number of 
POMC cells positive for PDK1 staining was counted for at least 100 neurons from 2 mice for each genotype. 
red, lacZ (POMC neurons), green, PDK1, blue, DAPI. Original magnification, 630x. B) Quantification of PDK1 
expression in POMC neurons from lacZΔPOMC and PDK1:lacZΔPOMC mice. *, p ≤ 0.05. 
 
To confirm specificity of recombination, Western blot analysis for PDK1 was 
performed in peripheral tissues from control and PDK1ΔPOMC mice. PDK1 expression was 
unchanged between control and PDK1ΔPOMC mice in brain, liver, skeletal muscle and pancreas 
(Figure 7). Since the POMC neuron population is very small compared to total neuron 
number in the hypothalamus, there was also no change observable in hypothalamic PDK1 
expression between control and PDK1ΔPOMC mice, which is in agreement with other reports 
using POMC-Cre animals (151, 235) (Figure 7).  
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Figure 7: Unchanged PDK1 protein content in peripheral tissues and total brain.  
Western blot analysis of PDK1 and IR-β subunit expression (loading control) in hypothalamus (HYP), whole 
brain (BRAIN), liver (LIVER), skeletal muscle (SM) and pancreas (PANC) of PDK1fl∆neo/fl∆neo and PDK1ΔPOMC 
mice (n= 4 of each group). 
 
The POMC gene is also expressed in corticotrophs and melanotrophs of the pituitary, 
where the POMC protein is cleaved to generate ACTH or α-MSH, respectively (130, 238, 
244, 245). Since the POMC-Cre transgene also targets Cre expression to these two cell types 
of the pituitary, PDK1 deletion in hypothalamus and pituitary was detected by PCR-based 
analysis (Figure 8).  
ARC HIP PIT LIV AG SM HRT WAT KID
PDK1fl∆neo
PDK1∆
 
 
Figure 8: PDK1 deletion follows endogenous POMC expression.  
Detection of deletion of the PDK1 allele in PDK1ΔPOMC mice. DNA was extracted from the arcuate nucleus 
(ARC), hippocampus (HIP), pituitary (PIT), liver (LIVER), adrenal gland (AG), skeletal muscle (SM), heart 
(HRT), white adipose tissue (WAT) and kidney (KID) from a PDK1ΔPOMC mouse. Using a PCR strategy, the 
deleted allele could only be detected in the arcuate nucleus and the pituitary, but not in the other tissues (upper 
bands). 
 
PI3K and PDK1 signalling is involved in regulation of development, mitosis, 
apoptosis, and cell size in several cell types (78, 80, 246-248). To exclude the possibility that 
PDK1 deficiency leads to POMC neuron apoptosis and/or developmental changes, POMC-
Cre and PDK1ΔPOMC mice were crossed to a second reporter line, which expresses enhanced 
green fluorescent protein (GFP) only after Cre-mediated recombination of a transcriptional 
stop cassette (249). Quantification of GFP immunoreactive cells in hypothalami of GFPΔPOMC  
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and GFP:PDK1ΔPOMC mice revealed unaltered cell numbers at the time of weaning and in 
adult mice (Figure 9).  
 
 
 
 
 
 
 
 
 
 
 
Figure 9: PDK1 deletion does not affect generation and survival of POMC neurons.  
A) POMC cell counts in the arcuate nucleus of GFP reporter mice showed no difference between GFPΔPOMC and 
PDK1:GFPΔPOMC reporter mice at the age of 4 and 12 weeks (n= 3 of each genotype at each age). Results are 
expressed as number of neurons positive for GFP staining +/- SEM. B) Cre-mediated recombination was 
visualized by immunohistochemistry for GFP in brains of GFPΔPOMC and PDK1:GFPΔPOMC mice. Representative 
sections for GFPΔPOMC and PDK1:GFPΔPOMC mice are shown. Scale bars, 50µm.  
 
Taken together, PDK1ΔPOMC mice are a viable tool to analyze the role of PDK1-
dependent signalling in hypothalamic POMC neurons and pituitary melanotrophs and 
corticotrophs. 
 
3.2 Increased body weight and hyperphagia in young PDK1ΔPOMC mice 
 To investigate whether the role of the PI3K signalling cascade in energy homeostasis 
in POMC neurons is PDK1-dependent, body weight of control and PDK1ΔPOMC mice fed 
either normal chow diet (ND) or high-fat diet (HFD) was monitored. Shortly after weaning, 
PDK1ΔPOMC mice exhibited slightly but significantly increased body weight independently of 
diet. However, body weight of control and PDK1ΔPOMC mice converged over time (Figure 
10A, B). Consistent with the increased body weight of young PDK1ΔPOMC mice, these animals 
also exhibited elevated serum leptin and glucose concentrations at the age of 8 weeks (Figure 
10C, D). To address whether initially increased body weight of PDK1ΔPOMC mice resulted 
from increased energy intake, we determined food intake in these mice at 8 weeks of age, 
which revealed significant hyperphagia in PDK1ΔPOMC mice (Figure 10 F).  
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Figure 10: Increased body weight and hyperphagia in young PDK1ΔPOMC mice.  
A) Average body weight of PDK1fl∆neo/fl∆neo and PDK1ΔPOMC mice on ND (n= 16-20). B) Average body weight of 
PDK1fl∆neo/fl∆neo and PDK1ΔPOMC mice on HFD (n= 12-24). C) Blood glucose levels in 8 week old PDK1fl∆neo/fl∆neo 
(n= 21) and PDK1ΔPOMC (n= 16) mice. D) Serum leptin concentrations of PDK1fl∆neo/fl∆neo (n=17-20) and 
PDK1ΔPOMC (n= 10-13) mice at 8 and 18 weeks of age. E) Epigonadal fat pad weight and body weight in 
PDK1fl∆neo/fl∆neo (n=21) and PDK1ΔPOMC  (n= 13) mice on ND at the age of 18 weeks. F) Daily food intake in  
PDK1fl∆neo/fl∆neo (n=13;5) and PDK1ΔPOMC  (n= 7;4) mice on ND at 8 weeks and at 10-11 weeks of age. *, p ≤ 
0.05; **, p ≤ 0.01. 
 
 Analysis of hypothalamic neuropeptide expression in PDK1fl∆neo/fl∆neo and PDK1ΔPOMC 
mice revealed a significant reduction in POMC expression in the absence of any alteration in 
the expression of the orexigenic neuropeptides agouti-related protein (AgRP) (Figure 11). 
Thus, PDK1ΔPOMC mice initially develop transiently increased body weight as a consequence 
of hyperphagia caused by reduced hypothalamic POMC expression. 
 Since the body weights of male PDK1ΔPOMC mice were not distinguishable from 
PDK1fl∆neo/fl∆neo mice starting from 10 weeks of age, we next determined parameters of energy 
homeostasis in older mice. Surprisingly, food intake of PDK1ΔPOMC mice was not significantly 
                                                                                                                                         Results 
   53
 
different from controls at 10 weeks of age (Figure 10F). Strikingly, at 18 weeks of age, 
PDK1ΔPOMC mice exhibited significantly reduced epigonadal fat pad mass and lower serum 
leptin concentrations but unchanged body weight (Figure 10D, E). Hypothalamic expression 
of NPY, AgRP and TRH was again unchanged (Figure 18) also at 18 weeks of age, while 
hypothalamic POMC expression was still reduced by 80% in PDK1ΔPOMC mice compared to 
controls (Figure 11A). Thus, progressive reduction of body weight, food intake, serum leptin 
concentrations and epigonadal fat pad mass occurred in the presence of constantly reduced 
hypothalamic POMC expression. 
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Figure 11: POMC mRNA expression is impaired in PDK1ΔPOMC mice.  
A) Neuropeptide expression in male PDK1fl∆neo/fl∆neo and PDK1ΔPOMC mice on normal diet at the age of 8 and 18 
weeks as measured by Real-Time PCR (n= 5-11 per group). B) Hypothalamic POMC expression in male 
PDK1fl∆neo/fl∆neo and PDK1ΔPOMC  mice on ND or HFD at the age of 18 weeks as measured by Real-Time PCR 
(n= 4-5 per group). *, p ≤ 0.05; **, p ≤ 0.01. 
 
3.3 Secondary hypocortisolism in PDK1ΔPOMC mice 
 Given the paradoxical decline of initially increased body weight and hyperphagia in 
the presence of constantly repressed POMC transcription, possible mechanisms underlying 
this phenotype were investigated. Old PDK1ΔPOMC mice showed significantly increased 
insulin sensitivity during insulin tolerance tests (Figure 12A). Moreover, analysis of glucose-
stimulated insulin secretion (GSIS) revealed that although insulin secretion was lower 
compared to PDK1fl∆neo/fl∆neo mice, blood glucose concentrations were significantly lower than 
in control groups, further supporting that PDK1ΔPOMC mice exhibit dramatically increased 
peripheral insulin sensitivity and subsequent compensatory reduction of insulin secretion 
(Figure 12B, C).  
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Figure 12: Elevated insulin sensitivity in PDK1ΔPOMC mice.  
A) Relative blood glucose during an insulin tolerance test of PDK1fl∆neo/fl∆neo and PDK1ΔPOMC mice on ND (left 
panel) or HFD (right panel) at the age of 15 weeks (n= 7-15 per group). B) Serum insulin levels during glucose-
stimulated insulin secretion (GSIS) of female PDK1fl∆neo/fl∆neo (n= 5) and PDK1ΔPOMC (n= 5) mice at the age of 22 
weeks. C) Blood glucose levels at the beginning and the end of the glucose-stimulated insulin secretion 
experiment of female PDK1fl∆neo/fl∆neo (n= 5) and PDK1ΔPOMC (n= 5) mice. *, p ≤ 0.05; **, p ≤ 0.01. 
 
 Taken together, relative body weight loss and dramatically increased insulin 
sensitivity in older mice resembled key clinical features of severe hypocortisolism, since 
corticosterone/cortisol is a positive regulator of food intake and a negative regulator of insulin 
sensitivity (250, 251).   
 To elucidate if PDK1ΔPOMC mice suffer from reduced circulating corticosterone 
concentrations, blood samples from control and PDK1ΔPOMC mice at different ages were taken. 
Analysis of plasma corticosterone concentrations revealed a significant reduction in 
PDK1ΔPOMC mice compared to control mice already at the age of 3 weeks and corticosterone 
concentrations further decreased over time in PDK1ΔPOMC mice (Figure 13A, B). Moreover, 
analysis of stress-induced corticosterone release revealed that PDK1ΔPOMC mice exhibited a 
dramatic impairment in stress-induced corticosterone production (Figure 13A). Similarly, 
injection of an ACTH analogue (Synacthen) resulted in a largely blunted raise in plasma 
corticosterone concentrations in PDK1ΔPOMC mice, consistent with adrenal insufficiency 
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(Figure 13C). Taken together, this indicates that PDK1ΔPOMC mice exhibit critically reduced 
circulating corticosterone with further progressive loss into adulthood. 
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Figure 13: Reduced plasma corticosterone and adrenal ACTH insensitivity in PDK1ΔPOMC mice.  
A) Plasma corticosterone levels of PDK1fl∆neo/fl∆neo and PDK1ΔPOMC mice on ND before and after a stress test at 
the age of 12 weeks (n= 5-6 per group). B) Basal plasma corticosterone levels in PDK1fl∆neo/fl∆neo and PDK1ΔPOMC 
mice at the age of 3, 4 and 5 weeks (n= 5-10 per group). C) Plasma corticosterone levels in PDK1fl∆neo/fl∆neo and 
PDK1ΔPOMC mice after intraperitoneal injection of saline or an ACTH analogue (Synacthen) at the age of 12 
weeks (n= 5 per group). *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001. 
 
 Hypothalamic CRH is partially responsible for POMC expression and ACTH release 
from the pituitary after stress stimuli but not under basal conditions, as CRH knockout mice 
do not show any change in basal pituitary POMC expression (244). There was no difference 
in hypothalamic CRH expression between PDK1fl∆neo/fl∆neo and PDK1ΔPOMC mice at any age or 
diet, indicating that hypothalamic circuits are not responsible for the loss of circulating 
corticosterone in PDK1ΔPOMC mice (Figure 18). 
 Since changes in the function of corticotrophs of the pituitary were possibly 
responsible for hypocortisolism in PDK1ΔPOMC mice, the pattern of GFP expression in the 
pituitary of GFPΔPOMC mice and GFP:PDK1ΔPOMC mice was investigated. This analysis 
revealed a more than 90% reduction in GFP-positive corticotroph cells in GFP:PDK1ΔPOMC 
mice compared to GFPΔPOMC mice (Figure 14A, B). In the same vein, cells immunoreactive 
for ACTH were drastically reduced in PDK1ΔPOMC mice (Figure 14C). Consistent with the 
dramatic reduction in corticotroph number, Real-time PCR analysis of POMC mRNA 
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expression revealed a ~80% reduction of pituitary POMC mRNA expression in PDK1ΔPOMC 
mice compared to PDK1fl∆neo/fl∆neo mice (Figure 14 D).   
 Melanotroph numbers in the intermediate lobe of the pituitary were also reduced, but 
in accordance with the notion that even POMC knockout mice have a relatively faint change 
in pigmentation and fur color, we did not notice any obvious change in fur color or skin 
pigmentation of PDK1ΔPOMC mice (134).  
 Taken together, these findings demonstrate that PDK1 is essential for survival of 
corticotrophs and that POMC cell-restricted PDK1 deficiency results in secondary 
hypocortisolism: while PDK1 deficiency in hypothalamic POMC neurons affects POMC 
transcription and not cell survival, it primarily controls cell survival of corticotrophs and 
melanotrophs in the pituitary. 
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Figure 14: Loss of POMC cells in pituitaries of PDK1ΔPOMC mice.  
A) Immunohistochemistry for GFP from pituitary sections of GFPΔPOMC and GFP:PDK1ΔPOMC mice at 
approximately 12 weeks of age. Brown, horseradish peroxidase (GFP). Single corticotrophs are marked by 
arrows. Scale bar, 100µm. B) Quantification of GFP-positive corticotrophs from pituitary sections of GFPΔPOMC 
(n= 2) and GFP:PDK1ΔPOMC (n= 3) mice.  C) Immunohistochemistry for ACTH from pituitary sections of 
PDK1fl∆neo/fl∆neo and PDK1ΔPOMC mice at approximately the age of 8 weeks. Green, ACTH. At least 3 mice of 
each genotype were analysed. Scale bar, 100µm. AL, anterior lobe; PL, posterior lobe. D) Pituitary POMC 
expression in female and male PDK1fl∆neo/fl∆neo (n= 5-6) and PDK1ΔPOMC (n= 4-6) mice on normal or high-fat diet 
at 18 weeks of age as measured by Real-Time PCR. *, p ≤ 0.05; **, p ≤ 0.01. 
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3.4 Corticosterone replacement prolongs hyperphagia and increased body 
weight in PDK1ΔPOMC mice 
 To directly address, whether progressive hypocortisolism contributes to the 
normalization of hyperphagia and increased body weight of PDK1ΔPOMC mice, circulating 
corticosterone concentrations were restored in PDK1ΔPOMC mice. Therefore, osmotic mini 
pumps filled with corticosterone were implanted in 8 week old mice and corticosterone 
concentrations, body weight and food intake were subsequently monitored. Circulating 
corticosterone levels were similar one week after surgery between PDK1fl∆neo/fl∆neo mice and 
PDK1ΔPOMC mice (Figure 15A) Two weeks after surgery, food intake and body weight was 
significantly increased in PDK1ΔPOMC mice, at a time where there is no significant difference 
between un-restored PDK1ΔPOMC mice and control mice (Figure 15B, C). Moreover, 
epigonadal fat pad mass was significantly increased in PDK1ΔPOMC mice three weeks after 
surgery (Figure 15 D).  
 Taken together, corticosterone restoration aggravates positive energy balance in 
PDK1ΔPOMC mice, indicating that in un-restored PDK1ΔPOMC mice the effect of reduced 
hypothalamic POMC expression is ameliorated by progressive loss of circulating 
corticosterone.  
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Figure 15: Corticosterone restoration maintains hyperphagia and increased body weight in PDK1ΔPOMC 
mice.  
A) Plasma corticosterone concentration in PDK1fl∆neo/fl∆neo and PDK1ΔPOMC mice before and after implantation of 
a corticosterone mini pump. Animals were bled at the age of 8 weeks, and surgery was performed immediately 
afterwards. Corticosterone levels were measured one and two weeks after surgery (n= 7-12 per genotype). B) 
Body weight of PDK1fl∆neo/fl∆neo and PDK1ΔPOMC mice before and after corticosterone minipump implantation (n= 
7-12 per genotype). C) Daily food intake of PDK1fl∆neo/fl∆neo and PDK1ΔPOMC mice before and after corticosterone 
minipump implantation (n= 7-12 per genotype). D) Epigonadal fat pad mass of PDK1fl∆neo/fl∆neo and PDK1ΔPOMC 
mice at the end of corticosterone restoration (three weeks after surgery, n= 7-10). *, p ≤ 0.05; **, p ≤ 0.01; ***, 
p ≤ 0.001. 
 
3.5 Restoration of energy homeostasis in PDK1ΔPOMC mice by FOXO1 
inhibition in vivo 
Next, experiments were designed to define the pathways acting downstream of PDK1 
to regulate hypothalamic POMC expression and/or corticotroph survival in the pituitary. 
Many kinases and transcription factors act downstream of PDK1, notably AKT, mTOR, 
S6K1, SGK1 and PKC isoforms and thus could contribute to the observed phenotype (247). 
Yet, one of the major mediators of PI3K signalling is the transcription factor FOXO1, which 
controls both expression of pro-apoptotic genes and has also been implicated in the control of 
POMC transcription (42, 50, 252, 253). As FOXO1 phosphorylation and exclusion from the 
nucleus is AKT-dependent, cells lacking PDK1 have increased FOXO1 activity. Therefore,  a 
mouse line for Cre-inducible expression of a dominant negative FOXO1 (FOXO1Δ256) mutant 
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was generated, which lacks the transactivation domain and the nuclear export signal (Figure 
16) (89). Expression of FOXO1Δ256 leads to its accumulation in the nucleus, where it binds to 
FOXO1 cis elements and inhibits binding of endogenous FOXO1 protein, thus precluding 
transactivation or -repression. FOXO1Δ256 mice were crossed with PDK1ΔPOMC mice to 
generate FOXO1Δ256:PDK1ΔPOMC mice, which specifically in POMC-expressing cells lack 
PDK1, but at the same time express FOXO1Δ256. 
 
CAGGs NeoR WSS IRES GFPFOXO1Δ256
CAGGs IRES GFPFOXO1Δ256
FOXO1∆256 GFP
after recombination mediated by Cre
mRNA
 
Figure 16: Generation of mice with inducible FOXO1Δ256 expression. 
Depicted is the knockin at the ROSA26 locus in mice with inducible FOXO1Δ256 expression. Note that Cre-
mediated recombination of the Neomycin resistance (Neo)/Westphal Stop sequence (WSS) cassette leads to 
expression of the FOXO1Δ256 protein but also to expression of GFP via an internal ribosome entry site (IRES), 
therefore GFP can be used for detection of FOXO1Δ256 expression. As only mice with one targeted allele were 
used, GFP expression is weaker than GFP expression from transgenic GFP reporter mice, which carry multiple 
integrations of the GFP transgene. CAGGS, chicken beta actin promoter/enhancer coupled with the 
cytomegalovirus immediate-early enhancer. 
 
Since the mRNA encoding the FOXO1Δ256 mutant also codes for GFP protein which is 
translated from an internal ribosome entry site (IRES), GFP immunohistochemistry can 
identify cells expressing the FOXO1Δ256 mutant (Figure 16).  
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Figure 17: Expression of FOXO1Δ256 rescues the hypothalamic phenotype of PDK1ΔPOMC mice.  
A) Cre-mediated recombination was visualized using immunohistochemistry for GFP in brains of GFPΔPOMC and 
FOXO1Δ256:PDK1ΔPOMC mice. Brown, horseradish peroxidase (GFP). Scale bar, 100µm. B) POMC cell counts in 
the Arc of GFP reporter mice showed no difference between GFPΔPOMC and FOXO1Δ256:PDK1ΔPOMC reporter 
mice at the age of 4 and 12 weeks (n= 3 per group). C) Average body weight of male PDKCre- (n= 19), 
PDK1ΔPOMC  (n= 15) and FOXO1Δ256:PDK1ΔPOMC (n= 8) mice on ND until 8 weeks of age. *p<0.05 between 
control and PDK1ΔPOMC; **p<0.01 between PDKCre- and PDK1ΔPOMC; #p<0.05 between PDK1ΔPOMC and 
FOXO1Δ256:PDK1ΔPOMC. D) Food intake of male PDKCre- (n= 9) and PDK1ΔPOMC (n= 10) and 
FOXO1Δ256:PDK1ΔPOMC (n= 7) mice on normal diet at 8 weeks of age. E) Blood glucose concentration of male 
PDK1fl∆neo/fl∆neo (n= 19), PDK1ΔPOMC (n= 15) and FOXO1Δ256:PDK1ΔPOMC (n= 8) mice on ND at the age of 8 
weeks. F) Relative expression of hypothalamic POMC and CART mRNA in male PDK1Cre- (n= 17), PDK1ΔPOMC 
(n= 15) and FOXO1Δ256:PDK1ΔPOMC (n= 7) mice on normal diet at 8 weeks of age as measured by Real-Time 
PCR. *, p ≤ 0.05; **, p ≤ 0.01. 
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Hypothalamic GFP-positive cell counts between FOXO1Δ256:PDK1ΔPOMC, 
GFP:PDK1ΔPOMC and GFPΔPOMC at the age of 4 or 12 weeks were similar, indicating 
appropiate expression of the FOXO1Δ256 mutant protein without an effect on POMC neuron 
number (Figure 9 and Figure 17A, B).  
Since young PDK1ΔPOMC mice showed increased body weight and hyperphagia, Cre-
negative (FOXO1Δ256):PDK1fl∆neo/fl∆neo, PDK1ΔPOMC and FOXO1Δ256:PDK1ΔPOMC littermates 
were analysed with regards to energy homeostasis. Body weight of FOXO1Δ256: 
PDK1fl∆neo/fl∆neo and PDK1fl∆neo/fl∆neo mice was indistinguishable, thus animals of both 
genotypes were combined into the control group (called PDK1Cre-). While PDK1ΔPOMC mice 
showed significantly increased body weight compared to control littermates, expression of 
FOXO1Δ256 restored normal body weight in FOXO1Δ256:PDK1ΔPOMC mice (Figure 17C). 
Similarly, FOXO1Δ256 expression prevented the hyperphagia in PDK1ΔPOMC mice (Figure 
17D). In the same line, mild hyperglycemia in PDK1ΔPOMC mice was ameliorated by 
FOXO1Δ256 expression in POMC cells (Figure 17E). 
Strikingly, while hypothalamic POMC expression was significantly decreased in 
PDK1ΔPOMC mice compared to PDK1Cre- mice, there was no significant difference between 
control and FOXO1Δ256:PDK1ΔPOMC mice (Figure 17F). Consistent with earlier observations, 
it was noticed that there was a strong tendency of decreased expression of the anorexigenic 
neuropeptide cocaine-and-amphetamine-related transcript (CART) in PDK1ΔPOMC  mice which 
was completely rescued in FOXO1Δ256:PDK1ΔPOMC mice (Figure 17F)(50). Similar to findings 
in PDK1ΔPOMC mice, hypothalamic expression of AgRP, NPY or CRH was not affected in 
FOXO1Δ256:PDK1ΔPOMC mice (Figure 18). 
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Figure 18: Unchanged orexigenic and PVN neuropeptide expression in PDK1ΔPOMC mice.  
Analysis of hypothalamic expression of the orexigenic neuropeptides AgRP, NPY as well as CRH and TRH in 
male PDK1fl∆neo/fl∆neo, PDK1ΔPOMC and FOXO1Δ256:PDK1ΔPOMC mice fed normal diet at the age of 8 weeks 
(NDw8), 18 weeks (ND), and at the age of 18 weeks fed high-fat diet (HFD) (n>= 5 per genotype). 
 
Overall, these in vivo findings indicate that regulation of FOXO1 activity in 
hypothalamic POMC neurons is the principal way by which PDK1 signalling controls energy 
homeostasis.  
 
3.6 Corticotroph cell loss in PDK1ΔPOMC mice is FOXO1-independent 
To investigate the effect of FOXO1Δ256 expression in corticotrophs, corticosterone 
levels in FOXO1Δ256:PDK1ΔPOMC mice were measured. FOXO1Δ256:PDK1ΔPOMC mice showed 
very low circulating corticosterone levels, similar to PDK1ΔPOMC mice (Figure 19A). GFP and 
ACTH stainings of pituitaries from FOXO1Δ256:PDK1ΔPOMC mice showed the same reduction 
in corticotrophs as seen in PDK1ΔPOMC mice, and POMC expression in the pituitaries was 
again significantly reduced in 8 week old mice (Figure 19B, C).  
To gain insights into the dynamics of corticotroph loss, gene expression patterns in 
pituitaries of 3 week old mice were analysed. POMC mRNA expression was already critically 
reduced at this age in both PDK1ΔPOMC and FOXO1Δ256:PDK1ΔPOMC mice (Figure 20). 
Strikingly, increased pituitary expression of the pro-apoptotic genes Bax and Bak was found 
in PDK1ΔPOMC mice but not FOXO1Δ256:PDK1ΔPOMC mice (Figure 20). Moreover, only 
PDK1ΔPOMC mice, but not FOXO1Δ256:PDK1ΔPOMC mice exhibited a tendency for increased 
expression of the pro-apoptotic gene Zac1, which has been shown to be under negative 
control of PI3K in pituitary cells in vitro (Figure 20) (254). Taken together, while increased 
expression of several pro-apoptotic genes in pituitaries of PDK1ΔPOMC mice can be rescued by 
expression of FOXO1Δ256, survival of corticotrophs appears to depend on additional PDK1-
dependent, FOXO1-independent pathway(s).  
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Figure 19: Corticotroph loss is not FOXO1-dependent in PDK1ΔPOMC mice. 
A) Serum corticosterone levels in male PDK1fl∆neo/fl∆neo, PDK1ΔPOMC and FOXO1Δ256:PDK1ΔPOMC mice fed 
normal diet at the age of 8 weeks (n= 8, 1, 2). B) Expression of ACTH was visualized by immunohistochemistry 
for ACTH in pituitaries of FOXO1Δ256ΔPOMC mice (which served as control) and FOXO1Δ256:PDK1ΔPOMC mice. 
Shown are representative stainings from 3 mice for each genotype. Blue, DAPI; green, ACTH. Original 
magnification, 100x. AL, anterior lobe; PL, posterior lobe. C) Expression of the FOXO1Δ256-transgene was 
visualized by immunohistochemistry for GFP in pituitaries of FOXO1Δ256ΔPOMC mice (which served as control) 
and FOXO1Δ256:PDK1ΔPOMC mice. Shown are representative stainings from 3 mice for each genotype. Brown, 
horseradish peroxidase (GFP). Single GFP-positive cells are indicated by arrows. Original magnification, 60x. 
AL, anterior lobe; PL, posterior lobe. 
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Figure 20: Pituitary pro-apoptotic gene expression in young PDK1ΔPOMC mice 
Relative expression of POMC and pro-apoptotic genes in pituitary extracts from male PDKCre- (n= 8) and 
PDK1ΔPOMC (n= 11) and FOXO1Δ256:PDK1ΔPOMC (n= 4) mice at the age of 3 weeks as determined by Real-Time 
PCR. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001. 
 
3.7 Hypothalamic JNK activity is increased by HFD 
 Since it was demonstrated that the interaction between FOXO1 and PI3K signalling is 
a critical regulator of energy homeostasis in the hypothalamus, further signalling pathways 
potentially impinging on FOXO1 and/or PI3K signalling were investigated. FOXO1 is 
directly phosphorylated by c-jun N-terminal (JNK) kinases which promotes its nuclear 
localisation and thus its ability to regulate transcription (88, 97). FOXO and JNK interaction 
has been shown to be important for life span expectancy, at least in invertebrates (97, 98, 
255). Since JNK has been shown to induce insulin resistance at the level of IRS protein 
through serine phosphorylation, JNK action could potentially negate PI3K activation both 
proximal (IRS) and distal (FOXO) to IR signalling (199, 256). JNK activation can be induced 
by hyperlipidemia, oxidative stress or inflammatory cytokine signalling, all of which have 
been reported to be present in hypothalamic tissue of diet-induced obese rodents (182, 214, 
257). To analyse if hypothalamic JNK activity is increased upon HFD feeding in mice, JNK 
kinase assays were performed. Hypothalamic JNK activity, as assessed by the ability of 
immunoprecipitated JNK to phosphorylate c-Jun in vitro, was significantly increased upon 
exposure to HFD for 8 weeks (Figure 21).  
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Figure 21: High-fat diet induces hypothalamic JNK activation 
A) High-fat diet (HFD) feeding increases hypothalamic JNK activation. C57bl/6 mice were either fed ND or 
HFD for 8 weeks, and hypothalami were microdissected. Total JNK activity in this tissue was measured by 
performing JNK kinase assays, and phosphorylation of the JNK target c-Jun was detected by immunoblot. 
JNK1/3 loading was used as input control. A representative immunoblot from one ND and one HFD animal is 
shown. B) Quantification of HFD-induced JNK activation in the hypothalamus. The ratio of p-c-Jun to JNK1/3 
input was quantified in Western blots of hypothalami from 8 ND and 8 HFD-fed animals as shown in A).  
*, p ≤ 0.05. 
 
3.8 HFD induces an inflammatory response in the hypothalamus 
 Aside from its induction by HFD, JNK is classically activated by stress signals and 
cytokines and is also capable to mediate cytokine expression itself (184, 198, 258). Therefore, 
hypothalamic expression of cytokines was determined in control and diet-induced obese mice. 
After 24 weeks of HFD, hypothalamic expression of TNFα and IL6 mRNA was significantly 
increased as was a marker of macrophage/microglia activation, lysozyme M (LysM) (Figure 
22A, B). Expression of the anti-inflammatory cytokine IL10 was unchanged by HFD, as was 
the microglia/macrophage marker F4/80 (Figure 22B).  
 Taken together, local cytokine expression is increased in hypothalami of diet-induced 
obese mice, indicating that besides increased influx of pro-inflammatory cytokines originating 
from the periphery, locally expressed cytokines may activate inflammatory signalling, leading 
to leptin and insulin resistance and thus exacerbating obesity. 
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Figure 22: High-fat diet induces hypothalamic transcription of cytokines 
A) Relative mRNA expression of TNFα and IL6 in hypothalami taken from wildtype mice fed ND or HFD for 
12 and 24 weeks as determined by Real-Time PCR. B) Relative mRNA expression of anti-inflammatory IL10 
and the macrophage/microglia marker F4/80 and MAC2, as well as the activation marker LysM in the 
hypothalami from wildtype mice fed ND or HFD for 12 weeks as determined by Real-Time PCR. *, p ≤ 0.05; 
**, p ≤ 0.01. 
 
3.9 TNFα has both anorexigenic and orexigenic properties in the CNS 
 Since hypothalamic TNFα expression was increased in diet-induced obese mice, and 
TNFα is also increased in the circulation of both obese rodent models as well as obese human 
patients (201, 208), the effect of icv injected TNFα was examined. To this end, vehicle, a low 
dose (2fMol) or a high dose (2pMol) of TNFα was applied icv into fasted animals, and food 
intake and body weight upon re-feeding were measured (Figure 23A). These dosages were 
based on previous work in rats, and also based on the notion, that TNFα concentrations 
eliciting strong activation of JNK or IKK in vitro are in the range of 0.05-2fMol/µl (214, 
259).  
 Compared to vehicle, high dose TNFα blunted re-feeding and body weight gain 
(Figure 23B, C). This is in good agreement with previous reports that high doses of TNFα are 
involved in mediating fever and sepsis-induced anorexia (216, 218). In contrast, low dose 
TNFα increased food intake and body weight gain after 4h or 24h refeeding (Figure 23B, C).  
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Figure 23: TNFα elicits orexigenic and anorexigenic effects in a dose-dependent manner 
A) Scheme of surgery, injection schedule and experimental paradigm. B) Vehicle, low (2fMol) or high (2pMol) 
TNFα doses were icv injected into 9 week old wild type mice after an overnight fast, and food intake was 
measured 4 and 24 later. C) Body weight changes in the experimental paradigm depicted in A) and B). (n= 13, 
20, 11). *, p ≤ 0.05; ***, p ≤ 0.001. 
 
 
3.10 HFD-induced hypothalamic expression of cytokines is not readily 
reversible 
 The increase in hypothalamic cytokine mRNA expression induced by HFD may be 
caused by hyperlipidemia, hyperglycemia or increased circulating proinflammatory cytokines 
found in obese animals and patients (190, 211, 260-262). To further define the cause 
underlying this increased expression of cytokines, an experimental paradigm was designed in 
which mice were subjected to HFD for 20 weeks, followed by 50% of these mice being 
subjected to ND (denoted as HFD->ND), whereas all other mice continued to be fed HFD 
(denoted HFD). After 3 weeks of ND, the HFD->ND group showed significantly decreased 
body weight and glucose tolerance as measured by GTT (Figure 24A-C). Hypothalamic 
cytokine expression was evaluated in HFD and HFD->ND mice. Compared to the HFD 
group, expression of TNFα was even further elevated, whereas expression of the anti-
inflammatory cytokine IL10 was reduced compared to the HFD group (Figure 24D). While 
expression of the macrophage markers F4/80 and Mac2 was unchanged between groups, a 
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significant decrease in LysM expression was noted, which might indicate decreased activation 
of local macrophages/microglia cells. Taken together, inflammatory cytokine expression of 
the hypothalamus is not readily reversed by a reduced uptake of dietary lipids at a time when 
body weight and glucose homeostasis are significantly improved, but instead shows further 
up-regulation of TNFα expression.  
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Figure 24: Diet-induced up-regulation of cytokine expression is not readily reversible by diet modulation 
A) Wildtype mice were fed HFD for 20 weeks. Half of the group (n= 8) were then fed ND for 4 weeks while the 
other group continued to feed on HFD, and a GTT was performed. B) GTT in both groups one week before half 
the group was switched onto ND. C) Body weights of both groups one week before (-1w) and three weeks after 
the switch (+3w). D) Relative hypothalamic expression of cytokines and macrophage markers was measured by 
Real-Time analysis in both groups of mice (n= 8 per group). *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001. 
 
3.11 Generation of JNK1ΔNES mice 
 Conventional JNK1 knockout animals are protected against diet-induced obesity and 
glucose intolerance (199). Both saturated lipids as well as inflammatory cytokines are able to 
activate JNK signalling (205, 260). To further investigate the role of hypothalamic JNK1 
signalling, mice with central ablation of JNK1 were created. To this end, mice were generated 
in which exon 2 of JNK1 is flanked by loxP sites (JNK1fl/fl mice, kindly provided by Dr. T. 
Wunderlich; Figure 25A). Cre-mediated deletion of exon 2 leads to a frame shift and a 
premature STOP codon, inhibiting expression of normal JNK1 protein. JNK1fl/fl mice were 
crossed with Nestin-Cre mice to generate mice homozygous for the loxP flanked exon 2 of 
the JNK1 gene and heterozygous for the Nestin-Cre transgene (denominated as JNK1ΔNES 
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mice) (Figure 25B). Littermates lacking the Nestin-Cre transgene were used as controls 
(genotype JNK1fl/fl, denominated as controls). 
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Figure 25: Nestin cell-specific deletion of JNK1 
A) In JNK1fl/fl mice, exon 2 is flanked by loxP sequences. Cre-mediated ablation of this exon will induce a 
frame-shift, leading to a premature stop of translation. B) Nestin-Cre mice are carriers of a Nestin-Cre transgene 
in which a Cre expression cassette was inserted into the translational initiaton site (ATG) of Nestin exon 1. Exon 
2 of the Nestin gene contains a known enhancer of Nestin gene expression. 
 
 Nestin-Cre mice express the Cre recombinase under control of the Nestin promoter, 
which, at the time of generation of these mice, was thought to be neuron-specific (239). To 
ascertain that presence of the Nestin-Cre transgene itself has no effect on weight regulation on 
its own, body weight of mice with and without the transgene was monitored. In accordance 
with previous reports, there was no difference in body weight between mice with or without 
the transgene (Figure 26A) (56, 263). Efficient JNK1 protein ablation and severely decreased 
JNK1 mRNA expression was detected in the brain of JNK1ΔNES mice, whereas JNK1 
expression was unchanged in peripheral tissues such as liver and skeletal muscle (Figure 26B, 
C). In addition to neurons, the Nestin gene is also expressed in a subset of pituitary stem cells, 
allowing deletion of target genes in all cell types of the adult pituitary using Nestin-Cre 
transgene animals (264). In line with this, deletion of JNK1 was detected in pituitaries of 
JNK1ΔNES mice using a PCR-based analysis (Figure 26D).  Taken together, JNK1ΔNES mice 
are a novel tool to study the role of neuronal and pituitary JNK1 signalling in vivo. 
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Figure 26: Generation of JNK1ΔNes mice. 
A) Presence of Nestin-Cre construct or the loxP flanked JNK1 exon does not impair body weight control. Body 
weight of wild type, Nestin-Cre transgenic, control and JNK1∆NES mice at the age of 6 weeks is shown (n>= 4 per 
group). B) Hypothalamic expression of JNK 1, 2 and 3 in JNK1fl/fl and JNK1∆NES mice (n=6 per group) as 
measured by real-Time PCR. C) Western blot analysis of JNK1/3 and IR-β or β-actin expression (loading 
control) in whole brain, liver and skeletal muscle (SM) of JNK1∆NES and JNK1fl/fl mice (n=4 per group). Note that 
since no JNK1-specific antibody is available, an antibody with dual JNK1 and JNK3 specificity was used. D) 
Deletion of the JNK1 allele in the pituitary of JNK1∆NES mice. After DNA extraction from the pituitary, PCR was 
used to detect the deleted JNK1 allele (ΔJNK1), the loxP flanked JNK1 alleles as well as presence of the Nestin-
Cre transgene. *, p ≤ 0.05; ***, p ≤ 0.001. 
 
3.12 JNK activity is increased in pituitaries of diet-induced obese mice 
 Since the Nestin-Cre transgene targeted JNK1 ablation also to pituitary stem cells, it 
was investigated if JNK activity is up-regulated in pituitaries from diet-induced obese mice. 
Pituitary JNK activity, as assessed by the ability of immunoprecipitated JNK to phosphorylate 
c-Jun in vitro, was significantly increased upon exposure to HFD, mirroring the effect of HFD 
on hypothalamic JNK activity (Figure 27). Thus, JNK1ΔNES mice are a suitable tool to analyze 
the role of HFD-induced activation of JNK signalling in the hypothalamus and pituitary. 
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Figure 27: Pituitary JNK activation upon high-fat feeding 
A) High-fat diet (HFD) feeding increases pituitary JNK activation. C57BL/6 mice were either fed ND or HFD 
for 8 weeks, and pituitaries were isolated. Total JNK activity in this tissue was measured by performing JNK 
kinase assays, and phosphorylation of the JNK target c-Jun was detected by immunoblot. JNK1/3 loading was 
used as input control. A representative immunoblot from one ND and one HFD animal is shown. B) 
Quantification of HFD-induced JNK activation in the pituitary. The ratio of p-c-Jun to JNK1/3 input was 
quantified in Western blots of pituitaries from 4 ND and 4 HFD-fed animals as shown in A). *, p ≤ 0.05. 
 
3.13 Unchanged behaviour in JNK1ΔNES mice 
 JNKs are involved in the development of brain structures, since mice lacking 2 out of 
the three JNK isoforms show severe brain defects (265). To determine if behaviour of 
JNK1ΔNES mice was affected, which might impair their ability to find food, or increase body 
weight in case of reduced spontaneous activity, several behavioural tests were performed.  
To study locomotor control, control and JNK1ΔNES mice were subjected to the Rotarod setup. 
In this experiment, mice are put on a at the beginning slowly rotating rod, which accelerates 
over time. The time on the rod was monitored. Control and JNK1ΔNES mice kept on the rod for 
the same time, indicating unchanged locomotor control (Figure 28A).  
 To examine anxiety behaviour, both control and JNK1ΔNES mice were subjected to the 
elevated zero maze paradigm, in which mice are put on an elevated ring, which has two 
closed and two open sides. Using an automated video-based system, the time in which the 
mouse was in the closed or the open part was measured. To avoid predators, mice tend to stay 
in the closed part of the maze, and accordingly, control mice stayed in the closed part for an 
average of 90% of the time. JNK1ΔNES mice also strongly preferred to stay in the closed part 
of the maze, indicating unchanged anxiety behaviour (Figure 28B). 
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Figure 28: Unchanged locomotor control and anxiety in JNK1ΔNes mice 
A) Rotarod analysis of control and JNK1∆NES mice. Control and JNK1∆NES mice were mounted on the Rotarod, 
and total time on the rotating rod until mouse fell from the rotarod was measured (n= 8 per group). B) Zero maze 
analysis of control and JNK1∆NES mice. Control and JNK1∆NES mice were put on the zero maze, and the time in 
which the mouse stayed in the closed part of the maze was tracked by an automatic visual system. n= 8 per 
genotype. 
 
 Since JNKs are involved in brain development, learning and memory recovery was 
tested using the Morris water maze paradigm (265). In this test, mice are put into a round pool 
filled with water which is divided into four quadrants. In one quadrant, a platform is 
submerged. Mice dislike swimming, therefore search for the platform, on which they come to 
rest. During daily trials, mice are put into different quadrants of the pool, and learn to find the 
hidden platform using localisation markers, which are permanently structured around the 
pool. In line with this, control mice found the platform 50% faster at the end of the trial 
compared to day 1 (Figure 29A). JNK1ΔNES mice performed similar, indicating unimpaired 
memory (Figure 29A). On the last day of trials, the platform was removed, and the time each 
mouse spent in the correct quadrant (searching for the platform) was measured. Control and 
JNK1ΔNES mice performed similarly, indicating unchanged spatial memory and memory 
retrieval in JNK1ΔNES mice (Figure 29B). Taken together, JNK1ΔNES mice show normal 
anxiety, locomotor and learning behaviour. 
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Figure 29: Unchanged water maze performance by JNK1ΔNes mice 
A) Morris water maze analysis of control and JNK1∆NES mice. Control and JNK1∆NES mice were trained daily for 
4 days to memorize the location of the platform, and the time taken by each mouse to find the platform was 
measured by an automatic, software based system (n= 8 per group). B) On the fifth day of the Morris water maze 
analysis, the platform was removed from the pool, and the time the mouse swam in the quadrant in which the 
platform had been was automatically measured by an automatic, software based system (n= 8 per genotype). 
 
3.14 Decreased weight but unchanged body composition in JNK1ΔNES mice 
 To gain insight into the effect of neuronal and pituitary JNK1 signalling in the control 
of energy homeostasis, body weight was monitored in control and JNK1ΔNES mice. JNK1ΔNES 
mice showed reduced body weight at the time of weaning, and continued to show decreased 
body weight until the end of the study at the age of 16 weeks (Figure 30A). Although body 
weight was decreased, nuclear magnetic resonance (NMR) analysis revealed unchanged body 
composition between control and JNK1ΔNES mice, indicating that the reduction in body weight 
is not due to loss of fat or lean mass (Figure 30B). In line with this finding, food intake when 
corrected for lean mass was unchanged (Figure 30C). Calorimetric analysis of control and 
JNK1ΔNES mice showed a strong tendency to increased oxygen consumption during the night 
in JNK1ΔNES mice, although this did not reach statistical significance (Figure 30D). Fuel 
preference as determined by respiratory quotient as well as activity was comparable between 
both groups (Figure 30E, F).  
 Taken together, JNK1ΔNES mice show decreased body weight but unchanged body 
composition and food intake with only minor increases in energy expenditure when fed ND. 
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Figure 30: Decreased weight but unchanged body composition in JNK1ΔNES mice on Normal Diet 
A) Average body weight of JNK1fl/fl and JNK1∆NES mice on normal diet (n= 12 per group). B) Body fat content 
of JNK1fl/fl and JNK1∆NES mice on normal diet at the age of 16 weeks as measured by nuclear magnetic 
resonance (NMR) analysis (n= 12 per group). C) Relative food intake of JNK1fl/fl and JNK1∆NES  mice on normal 
diet at the age of 13 weeks  (n= 8 per group). Relation of food intake to body weight was calculated individually 
for each mouse. D) Daily and nightly oxygen consumption of JNK1fl/fl and JNK1∆NES mice on normal diet at the 
age of 13 weeks (n= 8 per group). Oxygen consumption was calculated per gram lean mass of each individual 
mouse. E, F) Daily and nightly respiratory quotient (RER) and activity of control and JNK1∆NES mice on normal 
diet at the age of 13 weeks (n= 8 per group). **, p ≤ 0.01; ***, p ≤ 0.001. 
 
3.15 Improved glucose homeostasis in JNK1ΔNES mice under ND conditions 
 Hypothalamic insulin signalling regulates peripheral glucose production, uptake and 
insulin sensitivity (32, 102, 126, 151, 166). Since CNS JNK1 may be a negative regulator of 
insulin signalling, glucose homeostasis of control and JNK1ΔNES mice was measured. 
JNK1ΔNES mice showed reduced random and fasted blood glucose levels at all ages tested 
(Figure 31A). Whereas both control and JNK1ΔNES mice performed as well during GTTs, 
JNK1ΔNES mice also showed improved insulin sensitivity as measured by ITTs accompanied 
by reduced circulating insulin concentrations (Figure 31B-D). Taken together, JNK1ΔNES mice 
show increased insulin sensitivity and improved glycemic control when fed ND. 
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Figure 31: Improved insulin sensitivity and glycemic control in JNK1ΔNES mice on Normal Diet 
A) Fasted and fed blood glucose concentration of JNK1fl/fl and JNK1∆NES mice on normal diet at the indicated 
ages (n= 10-17 per group). B) Intraperitoneal glucose tolerance test in JNK1fl/fl and JNK1∆NES mice on normal 
diet at the age of 14 weeks (n= 9-10 per group). C) Intraperitoneal insulin tolerance test in JNK1fl/fl and 
JNK1∆NES mice on normal diet at the age of 15 weeks (n= 9-10 per group). D) Serum insulin concentrations in 
JNK1fl/fl and JNK1∆NES mice on normal diet at the age of 8 weeks (n= 8 per group). *, p ≤ 0.05; **, p ≤ 0.01- 
 
3.16 JNK1ΔNES mice show decreased body weight but are not protected from 
diet-induced obesity 
 JNK1ΔNES mice demonstrated elevated insulin sensitivity, and mildly reduced glucose 
levels as well as reduced body weight when fed ND. To examine if JNK1ΔNES mice are 
protected from diet-induced obesity and the associated glucose intolerance, control and 
JNK1ΔNES mice were fed HFD after weaning. Again, JNK1ΔNES mice showed significantly 
decreased body weight compared to controls (Figure 32A). Nonetheless, NMR analysis 
revealed no differences in fat content compared to controls, indicating that JNK1ΔNES mice are 
not protected from diet-induced obesity (Figure 32B). Food intake, when normalized for lean 
mass, was also comparable between control and JNK1ΔNES mice (Figure 32C). Calorimetric 
analysis revealed significantly increased oxygen consumption in JNK1ΔNES mice even when 
corrected for lean body mass (Figure 32D), while fuel preference or activity was similar 
between groups (Figure 32E, F). Taken together, JNK1ΔNES mice are not protected from diet-
induced obesity, but show increased energy expenditure during HFD feeding. 
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Figure 32: Decreased weight but unchanged body composition in JNK1ΔNES mice on HFD 
A) Average body weight of JNK1fl/fl and JNK1∆NES mice on high-fat diet (n= 12 per group). B) Body fat content 
of JNK1fl/fl and JNK1∆NES mice on high-fat diet at the age of 16 weeks as measured by nuclear magnetic 
resonance (NMR) analysis (n= 12 per group). C) Relative food intake of JNK1fl/fl and JNK1∆NES  mice on high-
fat diet at the age of 13 weeks  (n= 8 per group). Relation of food intake to body weight was calculated 
individually for each mouse. D) Daily and nightly oxygen consumption of JNK1fl/fl and JNK1∆NES mice on high-
fat diet diet at the age of 13 weeks (n= 8 per group). Oxygen consumption was calculated per gram lean mass of 
each individual mouse. E, F) Daily and nightly respiratory quotient (RER) and activity of control and JNK1∆NES 
mice on high-fat diet diet at the age of 13 weeks. n= 8 per group. *, p ≤ 0.05; ***, p ≤ 0.001. 
 
3.17 Improved glucose homeostasis in obese JNK1ΔNES mice 
 Since JNK1ΔNES mice showed improved glucose homeostasis under normal diet 
conditions, glucose tolerance tests were performed with control and JNK1ΔNES mice fed HFD. 
These experiments revealed significantly improved glucose clearance in JNK1ΔNES mice 
(Figure 33A). In line with this finding, fasting and random fed glucose concentrations were 
reduced in JNK1ΔNES mice compared to controls at all ages tested (Figure 33B). JNK1ΔNES 
mice also performed better in ITTs and showed reduced circulating insulin concentrations, 
indicating improved insulin sensitivity under HFD conditions (Figure 33C, D). Taken 
together, JNK1ΔNES mice are protected from obesity-induced glucose intolerance and insulin 
resistance. 
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Figure 33: Improved glucose tolerance and insulin sensitivity in obese JNK1ΔNES mice 
A) Intraperitoneal glucose tolerance test in JNK1fl/fl and JNK1∆NES mice on high-fat diet at the age of 14 weeks 
(n= 10 per group). B) Fasted and fed blood glucose concentration of JNK1fl/fl and JNK1∆NES mice on high-fat diet 
at the indicated ages (n= 10-17 per group). C) Intraperitoneal insulin tolerance test in JNK1fl/fl and JNK1∆NES 
mice on high-fat diet at the age of 15 weeks (n= 9-10 per group). D) Serum insulin concentrations in JNK1fl/fl 
and JNK1∆NES mice on high-fat diet at the age of 10 weeks (n= 8 per group). *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 
0.001. 
 
3.18 JNK1ΔNES mice show increased hypothalamic insulin but not leptin 
sensitivity 
 Hypothalamic leptin and insulin signalling is able regulate peripheral glucose 
homeostasis (32, 102, 126, 151, 166, 266, 267). Since JNK1ΔNES mice showed improved 
glucose homeostasis under both ND and HFD conditions, improvement of hypothalamic 
insulin and/or leptin sensitivity might underlie this phenotype. Therefore, intraperitoneal 
leptin sensitivity tests were performed. Both control and JNK1ΔNES mice fed HFD reacted to 
repeated leptin injections with only minor body weight or food intake reductions (Figure 34A, 
B), indicating leptin resistance in both groups. To further evaluate hypothalamic leptin 
sensitivity, indwelling cannulas were used to inject leptin into the lateral ventricle (icv), and 
food intake and body weight was monitored 24h later. Control and JNK1ΔNES mice fed ND 
showed similarly reduced body weight and food intake upon leptin treatment, indicating that 
also under ND conditions, JNK1ΔNES mice do not show increased leptin sensitivity, which was 
in line with unchanged serum leptin concentrations under ND conditions (Figure 34C-E).  
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Figure 34: Unaltered leptin sensitivity in JNK1ΔNES mice 
A, B) Changes in food intake and body weight after intraperitoneal leptin treatment in control and JNK1ΔNes mice 
on high-fat diet at the age of 13 weeks (n=8 per group). Data represent daily food intake after a 3-day treatment 
with twice-daily injections of saline or 2 mg/kg leptin. Body weight was measured twice a day. C) 24h food 
intake after icv leptin treatment in JNK1fl/fl (n= 5) and JNK1∆NES mice (n=4) mice on normal diet at the age of 12 
weeks. Mice were injected with either vehicle or 2µg leptin immediately before onset of dark phase, and food 
intake was measured 24h later. D) Body weight loss 24h after icv leptin treatment in JNK1fl/fl (n= 5) and 
JNK1∆NES mice (n= 4) mice on normal diet at the age of 12 weeks. Mice were injected with either vehicle or 2µg 
leptin immediately before onset of dark phase, and body weight was measured 24h later. Shown is fold change 
of body weight after leptin injection compared to vehicle injection. E) Serum leptin concentration of JNK1fl/fl 
and JNK1∆NES mice on normal diet at the age of 12 weeks (n= 8 per group). *, p ≤ 0.05. 
 
 In the same experimental paradigm, insulin was applied icv to both control and 
JNK1ΔNES mice. The specific amount of insulin (2mU on ND/4mU on HFD) was chosen, 
since earlier observations indicated no effect on food intake and body weight 24h after icv 
injection of these boluses (Jens C. Brüning, personal communication). In line with these 
findings, icv insulin injection did not change body weight or food intake compared to vehicle 
in control animals fed ND or HFD (Figure 35A-D). In contrast, JNK1ΔNES mice fed either ND 
or HFD showed significantly reduced body weight and food intake even 24h after insulin 
injection (Figure 35A-D).   
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Figure 35: Elevated hypothalamic insulin sensitivity in JNK1ΔNES mice 
A) 24h food intake after icv insulin treatment in JNK1fl/fl (n= 9) and JNK1∆NES (n=8) mice on normal diet at the 
age of 12 weeks. Mice were injected with either vehicle or 2mU insulin immediately before onset of dark phase, 
and food intake was measured 24h later. B) Body weight loss 24h after icv insulin treatment in JNK1fl/fl (n= 9) 
and JNK1∆NES (n= 8) mice on normal diet at the age of 12 weeks. Mice were injected with either vehicle or 2mU 
insulin immediately before onset of dark phase, and body weight was measured 24h later. Shown is percent 
change of body weight after insulin injection compared to vehicle injection. C) 24h food intake after icv insulin 
treatment in JNK1fl/fl (n= 5) and JNK1∆NES (n=5) mice on high-fat diet at the age of 10 weeks. Mice were injected 
with either vehicle or 4mU insulin immediately before onset of dark phase, and food intake was measured 24h 
later. D) Body weight change 24h after icv insulin treatment in JNK1fl/fl (n= 5) and JNK1∆NES (n= 5) mice on 
high-fat diet at the age of 10 weeks. Mice were injected with either vehicle or 4mU insulin immediately before 
onset of dark phase, and body weight was measured 24h later. Shown is percent change of body weight after 
insulin injection compared to aCSF injection. E) Hypothalamic AKT activation upon icv insulin treatment is 
improved in JNK1∆NES mice. JNK1fl/fl and JNK1∆NES mice on high-fat diet at the age of 10 weeks were fasted for 
48h, injected with aCSF or 4mU insulin and sacrificed 20min later. Immunoblot was performed for 
phosphorylated (activated) AKT, total AKT and β-actin protein content. F) Quantification of insulin-induced 
AKT phosphorylation compared to total AKT content shown in E). *, p ≤ 0.05; **, p ≤ 0.01. 
 
 To further assess if hypothalamic insulin action was improved in JNK1ΔNES mice, 
control and JNK1ΔNES mice were fasted for 48h to reduce background AKT phosphorylation, 
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injected with insulin, and sacrificed 20min later. Western blot analysis revealed improved 
insulin-mediated AKT phosphorylation in JNK1ΔNES mice (Figure 35E, F). Taken together, 
JNK1 ablation improves hypothalamic insulin action. 
 
3.19 Unchanged hypothalamic expression of neuropeptides, cytokines and 
ER stress mediators in JNK1ΔNES mice  
 To determine if increased hypothalamic insulin sensitivity in concurrence with normal 
leptin sensitivity had a direct effect on local neuropeptide expression, Real-Time PCR was 
used to measure neuropeptide mRNA levels. No consistent changes in expression of POMC, 
AgRP or NPY were detected (Figure 36A).  Hypothalamic ER stress has been reported in 
obese mouse models (233). Similarly, HFD feeding led to increased expression of ER stress 
markers glucose-regulated protein 78kD (GRP78) and spliced (activated) XBP-1 (XBP-1s) in 
controls, and to the same extent in JNK1ΔNES mice, while expression of CHOP remained 
unaltered (Figure 36B). In wild type mice fed HFD for approximately 12-14 weeks, 
hypothalamic IL6 but not TNFα was elevated (Figure 22A). Accordingly, IL6 expression was 
increased by trend upon HFD feeding both in control and JNK1ΔNES mice, while TNFα was 
not altered (Figure 36C). Importantly, TNFα and IL6 expression was similar between 
genotypes.  
 Taken together, these findings indicate that hypothalamic ablation of JNK1 improves 
insulin sensitivity even in the unaltered presence of cytokine expression and ER stress.  
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Figure 36: Hypothalamic neuropeptide, cytokine and ER stress marker expression is unchanged in 
JNK1ΔNES mice 
A) Neuropeptide expression in the arcuate nucleus. Arcuate nuclei of control and JNK1∆NES mice either on 
normal chow or on high-fat diet were microdissected at the age of 16 weeks. Real-Time expression analysis of 
the anorexigenic neuropeptide proopiomelanocortin (POMC) and the orexigenic neuropeptides Neuropeptide Y 
(NPY) and Agouti-related protein (AgRP) was performed (n= 6 per group). B) Hypothalamic expression of ER 
stress markers. Hypothalami of control and JNK1∆NES mice either on normal chow or on high-fat diet were 
microdissected at the age of 16 weeks. Real-Time PCR expression analysis of the ER stress markers 
CCAAT/enhancer binding protein ε (CHOP), the chaperone glucose-regulated protein 78kD (GRP78) and 
spliced (activated) form of the X-box binding protein 1 (XBP-1s) was performed (n= 6 per group). C) Cytokine 
expression in the arcuate nucleus. Arcuate nuclei of control and JNK1∆NES mice either on normal chow or on 
high-fat diet were microdissected at the age of 16 weeks. Real-Time expression analysis of the cytokines tumor 
necrosis factor α (TNFα), Interleukin 6 (IL6) and Interleukin 1β (IL1β) was performed (n= 6 per group). *, p ≤ 
0.05; **, p ≤ 0.01. 
  
3.20 HFD induces ER stress in the pituitary in a JNK1-independent manner  
 Since JNK activation had been shown to take place in the pituitary of diet-induced 
obese animals, it was asked, if ER stress is induced in parallel. In line with diet-induced ER 
stress in the hypothalamus, mRNA expression of ER stress markers such as GRP78 and 
spliced XBP-1 were also increased in pituitaries of HFD-fed control animals (Figure 37). 
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Interestingly, CHOP, but not GRP78 expression was increased in in JNK1ΔNES mice fed ND. 
Nonetheless, JNK1ΔNES mice showed similar expression of ER stress markers under HFD 
feeding conditions, indicating that JNK1 deficiency does not protect from diet-induced ER 
stress in the pituitary (Figure 37).  
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Figure 37: HFD induces ER stress marker expression in the pituitary 
A) Pituitary expression of ER stress markers. Pituitaries of control and JNK1∆NES mice either on normal chow or 
on high-fat diet were microdissected at the age of 16 weeks. Real-Time expression analyses of the ER stress 
markers CHOP and GRP78 was performed (n= 6 per group). **, p ≤ 0.01; ***, p ≤ 0.001. 
 
3.21 JNK1ΔNES mice show decreased activation of the somatotrophic axis 
 JNK1ΔNES mice consistently showed decreased body weight both under ND and HFD 
conditions, although body composition was unchanged. Therefore, to assess if changes in 
longitudinal growth were responsible for this decrease in body weight, naso-anal length was 
measured in control and JNK1ΔNES mice at the age of 16 weeks. JNK1ΔNES mice showed 
significantly reduced naso-anal length (Figure 38A). Furthermore, it has been noted that diet-
induced obese rodents show increased linear growth compared to ND fed animals, although 
the mechanism underlying this phenotype is poorly defined (268, 269). While control animals 
were significantly longer when fed HFD, this increase in body length was blunted in 
JNK1ΔNES mice fed HFD, again pointing to differential control of the somatic growth axis 
(Figure 38A).  
 In control of somatic growth, hypothalamic neurons release growth hormone releasing 
hormone (GHRH) which acts on somatotrophs in the pituitary to produce and release growth 
hormone (GH). Growth hormone in turn acts on GH receptors on the liver, inducing insulin-
like growth factor (IGF)-1 transcription and release, which acts on chondrocytes to increase 
longitudinal growth (for review see (270)). One biomarker of the somatotrophic axis is serum 
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IGF-1, which was examined by ELISA. IGF-1 levels were decreased by 50% in JNK1∆NES 
mice (Figure 38B).  
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Figure 38: Serum IGF-1 is reduced in JNK1ΔNES mice 
A) Naso-anal length of JNK1fl/fl and JNK1∆NES on normal or high-fat diet at the age of 16 weeks (n= 9 per 
group). B) Serum IGF-1 concentrations of JNK1fl/fl (n= 10) and JNK1∆NES (n= 10) on normal diet either random 
fed or fasted at the age of 10 weeks. *, p ≤ 0.05; ***, p ≤ 0.001. 
 
 To determine if diminished GH was underlying this phenotype, circulating growth 
hormone was measured in both groups of mice. Despite considerable variation of GH 
concentrations in control mice, presumably due to the pulsatile secretion pattern of GH, 
JNK1∆NES mice showed strongly decreased levels of circulating GH (Fig. 39A).  
 Neuronal JNK1 ablation might potentially regulate expression of hypothalamic 
neuropeptides regulating the somatotrophic axis, namely GHRH and somatostatin, which can 
inhibit GH release (271). Nonetheless, hypothalamic mRNA expression of both peptides was 
unchanged, indicating that JNK1 mediated regulation of the somatotrophic axis does not 
occur on the hypothalamic level (Figure 39B). Therefore, pituitary GH mRNA expression was 
measured through Real-Time PCR analysis. In line with decreased GH and IGF-1 levels in 
circulation, decreased GH mRNA expression was detected in pituitaries of JNK1∆NES mice 
(Figure 39C).  
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Figure 39: Somatic growth is reduced at the control level of the pituitary in JNK1ΔNES mice 
A) Serum GH concentrations of JNK1fl/fl and JNK1∆NES on ND at the age of 10 weeks (n= 8 per group). B) 
Hypothalamic expression of GHRH and somatostatin of JNK1fl/fl and JNK1∆NES mice on ND at the age of 16 
weeks as measured by Real-Time PCR (n= 6 per group). C) Pituitary expression of GH of JNK1fl/fl and 
JNK1∆NES mice at the age of 16 weeks as measured by Real-Time PCR (n= 6 per group). *, p ≤ 0.05. 
 
 These findings could either be a consequence of reduced transcription, or of reduced 
survival of somatotrophs due to JNK1 ablation. Immunohistochemical analysis of GH 
positive cells revealed unaltered pituitary structure, indicating that cell loss does not account 
for the decrease in GH expression (Figure 40A). 
 In the face of unchanged GHRH expression but decreased GH production, an 
intermediate signalling molecule could be regulated in JNK1∆NES mice. The GHRH receptor 
(GHRHR) is crucial for the ability of GHRH to stimulate GH expression and release (272-
274). Pituitaries from JNK1∆NES mice showed decreased GHRHR expression compared to 
control mice fed either ND or HFD, indicating that decreased GHRHR signalling may 
underlie the decreases in circulating GH and subsequently IGF-1 (Figure 40B). Notably, 
GHRHR expression was elevated in diet-induced obese controls (Figure 40B). 
 To further understand regulation of GHRHR expression, mRNA levels of PIT-1, a 
critical regulator of GHRHR expression was determined (275). PIT-1 expression was reduced 
by 30% in pituitary of JNK1∆NES mice (Figure 40C). Taken together, JNK1∆NES mice show 
decreased somatotrophic GHRHR expression, and subsequently reduced GH and IGF-1 
serum levels and ultimately impaired somatic growth, indicating an unexpected critical role 
for pituitary JNK1 signalling in control of somatic growth and body length. 
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Figure 40: Pituitary expression of PIT-1 and its target GHRHR is regulated in JNK1ΔNES mice 
A) Immunohistochemistry for GH from pituitary sections of JNK1fl/fl and JNK1∆NES mice at the age of 16 weeks 
(Green, GH; blue, DAPI). At least 3 mice of each genotype were analysed (PL, posterior lobe; AL, anterior lobe; 
scale bar 80µm). B) Pituitary expression of GHRHR of JNK1fl/fl and JNK1∆NES mice fed ND or HFD at the age 
of 16 weeks as measured by Real-Time PCR (n= 6 per group). C) Pituitary expression of Pituitary-specific 
positive transcription factor 1 (PIT-1) of JNK1fl/fl and JNK1∆NES mice fed ND at the age of 16 weeks as measured 
by Real-Time PCR (n= 6 per group). ***, p ≤ 0.001. 
 
3.22 JNK1∆NES mice show increased activation of the thyroid axis 
 To further define the role of JNK1 in the pituitary, it was asked whether JNK1 
deficiency also affects other pituitary functions besides the somatrophic axis. As mentioned 
before, pituitary expression and release of the POMC cleavage product adrenocorticotrophic 
hormone (ACTH) stimulates release of adrenal corticosterone (in rodents) or cortisol (in 
humans) (136). Corticosterone and cortisol are known to be antagonists of insulin action, and 
loss of circulating corticosterone might explain the increased insulin sensitivity of JNK1∆NES 
mice. Nonetheless, corticosterone concentrations were unchanged between control and 
JNK1∆NES mice (Figure 41A), indicating that general pituitary function was not severely 
impaired.  
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Figure 41: Corticosterone levels are normal in JNK1ΔNES mice 
A) Unchanged circulating corticosterone in JNK1∆NES mice. Serum corticosterone in control and JNK1∆NES mice 
at the age of 10 weeks was measured by ELISA (n= 8 per group). 
 
 Besides somatotrophs and corticotrophs, thyrotrophs in the pituitary play an important 
role in energy homeostasis. Thyrotrophs are stimulated by hypothalamic thyroid releasing 
hormone (TRH) to express and release thyroid stimulating hormone (TSH) β, which acts on 
the thyroid gland, increasing circulating triiodothyronine (T3) (and thyroxine (T4)) levels, 
who eventually stimulate energy expenditure. Serum T3 levels were increased in JNK1∆NES 
mice (Figure 42A). In line with increased T3 levels and increased oxygen consumption as 
monitored by calorimetric analysis, brown adipocytes in interscapular brown adipose tissue 
(BAT) of JNK1∆NES mice appeared smaller, which is a hallmark of increased energy 
expenditure  (Figure 42B). Examination of BAT expression of uncoupling proteins revealed a 
trend for increased uncoupling protein (UCP)1 mRNA, which is crucial for energy dissipation 
by proton leakage across the mitochondrial membrane, but not in UCP2 and UCP3 mRNA 
levels, whose role in energy expenditure is controversial (276-278)(Figure 42C).  
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Figure 42: JNK1∆NES mice show increased activation of the thyrotropic axis 
A) Serum free T3 concentration of JNK1fl/fl and JNK1∆NES mice on ND at the age of 10 weeks (n= 8 per group). 
B) Representative H&E staining of brown adipose tissue of control and JNK1∆NES mice on HFD at the age of 16 
weeks. BAT sections of 3 mice per genotype were analysed. Scale bars, 40µm. C) Brown adipose tissue 
expression of UCP1, 2 and 3 of JNK1fl/fl and JNK1∆NES mice on HFD at the age of 16 weeks as measured by 
Real-Time PCR (n= 6 per group). ***, p ≤ 0.001. 
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 To find out if changes in hypothalamic mRNA expression of TRH were underlying the 
increased energy expenditure, Real-Time analysis was performed. This revealed no consistent 
change in TRH mRNA expression, again pointing to a pituitary autonomous phenotype 
(Figure 43A). In line with the finding of increased circulating T3 concentrations, a more than 
threefold increase of TSHβ mRNA expression was detected in pituitaries of JNK1∆NES mice 
(Figure 43B). Importantly, and inverse to what was found with pituitary GHRHR mRNA 
levels, TRH receptor (TRHR) expression was increased in pituitaries of JNK1∆NES mice 
(Figure 43C).  
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Figure 43: Elevated pituitary activation of the thyrotropic axis in JNK1∆NES mice 
A) Hypothalamic expression of TRH as measured by Real-Time PCR analysis (n= 5 per group). B) Pituitary 
expression of TSHβ of JNK1fl/fl and JNK1∆NES mice on on ND or HFD at the age of 16 weeks as measured by 
Real-Time PCR (n= 6 per group). C) Pituitary expression of TRHR of JNK1fl/fl and JNK1∆NES mice on ND or 
HFD at the age of 16 weeks as measured by Real-Time PCR (n= 6 per group). *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 
0.001. 
  
 Immunohistological analysis of TSHβ positive cells did not show significant structural 
alterations in pituitaries of JNK1∆NES mice, indicating that TRHR expression, but not a change 
in TSHβ cell number underlies the increased expression of TSHβ mRNA (Figure 44A). To 
study the pituitary cell-autonomous regulation of TRHR expression, a rat pituitary cell line 
(GH4C1) was employed which has been previously used to study TRHR expression (279). 
GH4C1 cells were incubated with vehicle, JNK inhibitor (SP600125), as well as PI3K 
(LY294002) and ERK (PD98059) inhibitors to gain further insight into control of TRHR 
expression. While incubation with either PI3K or ERK inhibitor did not have an effect on 
TRHR expression, incubation with a JNK inhibitor significantly increased TRHR expression 
by 70%, which is similar to the increase also seen in JNK1∆NES mice in vivo (Figure 44B). 
Thus, in line with the increase in pituitary TRHR expression of JNK1∆NES mice, this finding 
highlights the importance of JNK1-dependent signalling in pituitary-autonomous regulation 
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of the thyroid axis. Taken together, JNK1∆NES mice show increased thyroid action caused by 
an increase in pituitary TSHβ and TRHR expression.  
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Figure 44: JNK inhibition increases TRHR expression in vitro 
A) Immunohistochemistry for TSHβ from pituitary sections of JNK1fl/fl and JNK1∆NES mice at the age of 16 
weeks (Green, TSHβ; blue, DAPI). At least 2 mice of each genotype were analysed (Original magnification, 
100x. PL, posterior lobe; AL, anterior lobe). B) Expression of TRHR in the rat pituitary cell line GH4C1. 
Expression of TRHR was measured after 16h incubation with control (0.1% DMSO), JNK (SP600125), PI3K 
(LY294002) or ERK (PD98059) inhibitor. For each sample within an experiment, triplicate values were 
averaged and then the means of the Real-Time PCR results from three independent experiments were compared. 
*, p ≤ 0.05. 
 
3.23 JNK1∆Nes mice are protected from hepatic dysfunction upon HFD 
 Central and peripheral insulin sensitization as well as increased thyroid activity have 
been shown to protect from hepatic steatosis and deregulated gluconeogenesis during obesity, 
whereas GH action is thought to induce hepatic gluconeogenesis by its negative effect on 
insulin sensitivity, although very recently a direct role of GH on hepatic lipid and glucose 
metabolism has also been documented (151, 280-283). Therefore, hepatic tissue morphology 
in control and JNK1∆NES mice fed HFD was investigated. Relative liver weight was decreased 
in JNK1∆NES mice compared to controls, which could point to decreased lipid accumulation 
(Figure 45A). In line with this notion, Oil-Red O staining showed a reduction in stainable 
neutral lipids in livers of JNK1∆NES mice fed HFD (Figure 45B).  
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Figure 45: JNK1∆NES mice are protected from diet-induced hepatosteatosis 
A) Relative liver weight of JNK1fl/fl and JNK1∆NES mice on high-fat diet at the age of 16 weeks (n= 12 per 
group). Relation of liver mass to body weight was calculated individually for each mouse. B) Representative Oil 
red O staining of hepatic tissue of JNK1fl/fl and JNK1∆NES mice on high-fat diet at the age of 16 weeks (Original 
magnification 100x). Liver sections of 3 animals per genotype were analysed. **, p ≤ 0.01. 
 
 Chromatographic analysis of liver extracts revealed a specific reduction in 
diacylglyceride (DG) and triacylglyceride (TG) content in JNK1∆NES mice without changes in 
free fatty acids or cholesterol (Figure 46A, B).  
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Figure 46: Reduced hepatic triglyceride content in HFD-fed JNK1∆NES mice 
A) Hepatic triglyceride (TG) content of JNK1fl/fl and JNK1∆NES mice on high-fat diet at the age of 16 weeks (n= 
4 per group). B) Hepatic cholesterol, 1,2- and 1,3-Diacylglycerides (DG), and free fatty acid (FFA) content of 
JNK1fl/fl and JNK1∆NES  mice on high-fat diet at the age of 16 weeks (n= 4 per group). *, p ≤ 0.05; **, p ≤ 0.01. 
 
 Since JNK1∆NES mice also showed resistance to obesity-induced glucose tolerance, it 
was analysed if besides protection against hepatic steatosis, JNK1∆NES mice also exhibited an 
amelioration of obesity-associated elevations of hepatic glucose production (HGP). Hence, 
pyruvate tolerance tests (PTT) were performed in control and JNK1∆NES mice to investigate 
regulation of hepatic gluconeogenesis during fasting, since pyruvate is rapidly taken up and 
metabolized to glucose in livers of fasting animals. Importantly, JNK1∆NES mice showed 
significantly decreased glucose levels in PTTs, indicating that reduced HGP contributes to the 
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improved glucose homeostasis of JNK1∆NES mice (Figure 47A). Several groups have 
independently shown that insulin action on (AgRP) neurons decreases HGP via local 
expression of IL6 in liver (151, 163). In line with increased hypothalamic insulin action found 
in JNK1∆NES mice, significantly increased hepatic IL6 mRNA expression was found 
concurrent with mildly reduced expression of the key gluconeogenic enzyme glucose-6-
phosphatase (G6P) (Figure 47B).  
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Figure 47: Ameliorated hepatic glucose production in diet-induced obese JNK1∆NES mice 
A) Pyruvate tolerance test in JNK1fl/fl and JNK1∆NES mice on high-fat diet at the age of 10 weeks (n= 8-14 per 
group). B) Real-Time analysis of hepatic IL6 and G6P mRNA expression in JNK1fl/fl and JNK1∆NES mice on 
HFD at the age of 16 weeks (n= 8 per group). *, p ≤ 0.05; **, p ≤ 0.01. 
 
 Lastly, hepatic insulin sensitivity was directly assessed. After intraperitoneal insulin 
injection, liver of JNK1∆NES mice showed increased phosphorylation of the key insulin 
downstream target AKT, indicating that direct insulin action on liver is also retained under 
HFD conditions (Figure 48A, B). Taken together, hypothalamic and pituitary JNK1 
deficiency results in amelioration of obesity-induced hepatic steatosis and dysregulated HGP. 
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Figure 48: Elevated hepatic insulin sensitivity in diet-induced obese JNK1∆NES mice 
A) Hepatic AKT activation upon intraperitoneal insulin treatment is improved in diet-induced obese JNK1∆NES 
mice. JNK1fl/fl and JNK1∆NES mice on HFD at the age of 10 weeks were fasted for 16h, injected with saline or 
1.5U/kg body weight insulin and sacrificed 30min later. Immunoblot was performed for phosphorylated 
(activated) AKT and IR-β as loading control (n= 3 per injected group). B) Quantification of insulin-induced 
AKT phosphorylation compared to total IR-β content shown in A). *, p ≤ 0.05. 
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3.24 JNK1∆Nes mice are protected from HFD-induced adipose tissue 
inflammation and dysfunction 
 Research during the last 15 years has revealed that adipose tissue expresses and 
releases a plethora of hormones, called adipokines, with leptin being the most prominent one 
(284, 285). While leptin acts as a “messenger” of WAT to the brain, it has become clear that 
hormones acting in the brain also regulate adipose tissue metabolism. For example, insulin 
and leptin acting in the central nervous system regulate gene expression and lipid uptake in 
WAT, likely through the sympathetic nervous system (161, 286). One of these studies could 
show that chronic insulin infusion in the CNS, at a low dose that did not affect food intake, 
led to an increase in WAT expression of lipoprotein lipase (LPL), which catalyses a key step 
in lipid uptake into WAT (161). In line with this, epigonadal adipose tissue mass was 
reportedly increased after central insulin infusion (161). Since it was shown here that 
JNK1∆NES mice show increased central insulin sensitivity, the structure of white adipose tissue 
was further examined.  
 Although NMR studies had revealed unchanged relative fat content of control and 
JNK1∆NES mice fed HFD, relative eWAT (but not BAT) mass was increased in JNK1∆NES 
mice, indicating differential fat accumulation in these mice compared to control animals 
(Figure 49A). Notably, under fasting conditions, eWAT lipids appeared to be released at a 
higher rate compared to eWAT lipids from control animals, since fasting lead to a significant 
reduction in eWAT mass only in JNK1∆NES mice fed HFD (Figure 49B). 
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Figure 49: Increased eWAT mass in diet-induced obese JNK1∆NES mice 
A) Relative epigonadal white and brown adipose tissue weight of JNK1fl/fl and JNK1∆NES mice on high-fat diet at 
the age of 16 weeks (n= 12 per group). Relation of epigonadal adipose tissue mass and brown adipose tissue 
mass to body weight was calculated individually for each mouse. B) Absolute epigonadal adipose tissue mass of 
control and JNK1∆NES mice on high-fat diet at the age of 16 weeks either random fed or after overnight (16 hour) 
fasting (n= 8 per group). *, p ≤ 0.05. 
 
 Adipocyte size was monitored from control and JNK1∆NES mice on either diet. 
JNK1∆NES mice fed ND showed significantly increased adipocyte size (Figure 50A). This is in 
line with the notion that improved insulin sensitivity as induced by reduced GH levels can 
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lead to moderately increased lipid uptake and adipocyte size in human patients (287). In 
contrast, when adipocyte size was determined from animals fed HFD, adipocyte size from 
control animals was massively increased indicating lipid-induced hypertrophy, while 
adipocyte size of JNK1∆NES mice was comparable to ND adipocyte size (Figure 50B).  
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Figure 50: Obese JNK1∆NES mice are protected from adipocyte hypertrophy 
A) Representative H&E stain of epigonadal adipose tissue of control and JNK1∆NES mice on normal diet at the 
age of 16 weeks. Scale bar: 100 µm. B) Representative H&E stain of epigonadal adipose tissue of control and 
JNK1∆NES mice on high-fat diet at the age of 16 weeks. Scale bar: 100 µm. C) Quantification of adipocyte 
surface in epigonadal adipose tissue of JNK1fl/fl and JNK1∆NES mice on normal chow diet and high-fat diet at the 
age of 16 weeks (n= 3-6 per group). *, p ≤ 0.05; **, p ≤ 0.01. 
 
 To gain insight into this apparent discrepancy, expression of key enzymes involved in 
lipid uptake and lipolysis were measured. LPL regulates triglyceride breakdown, allowing 
transport of FFAs into adipocytes. LPL mRNA levels tended to be increased under ND 
conditions and were significantly elevated in eWAT from JNK1∆NES mice fed HFD compared 
to controls, indicating improved uptake of TGs into eWAT (Figure 51A). Although this might 
partially explain the increase in adipocyte size under ND conditions, adipocytes from 
JNK1∆NES mice fed HFD were smaller compared to controls. One key enzyme controlling 
lipid efflux from adipocytes is hormone sensitive lipase (HSL). HSL expression is reduced in 
WAT biopsies of insulin resistant patients, which is thought to render adipocytes unable to 
reduce TG storage levels, leading to lipid overload and inhibiting weight loss (288). In line 
with increased peripheral insulin sensitivity of JNK1∆NES mice, HSL mRNA levels were 
increased in eWAT taken from HFD fed JNK1∆NES mice (Figure 51A). Since eWAT mass 
changed more dynamically upon fasting in JNK1∆NES mice, these findings indicate that eWAT 
lipids are more readily accessible during periods of negative energy balance (by elevated HSL 
action). Taken together, eWAT adipocytes of JNK1∆NES mice are resistant to obesity-induced 
hypertrophy. 
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Figure 51: JNK1∆NES mice show ameliorated eWAT lipid metabolism enzyme expression 
A) Expression of lipoprotein lipase (LPL) and hormone-sensitive lipase (HSL) in epigonadal white adipose 
tissue of JNK1fl/fl and JNK1∆NES mice (n=8 per group) as measured by real-time PCR. *, p ≤ 0.05. 
 
 WAT inflammation is thought to be a crucial event in the pathophysiology of obesity 
and DM, since macrophage infiltration and local inflammation will eventually lead to 
systemic, low-grade chronic inflammation (202, 203, 208, 223). There is evidence that lipid 
overload leads to apoptotic death of adipocytes (209). In line with this finding, activated 
macrophages are frequently found around dead or dying adipocytes, appearing as crown-like 
structures (209). Since adipocyte lipid load was reduced in JNK1∆NES mice, it was 
hypothesized that eWAT inflammatation may be reduced. While control animals showed 
increased expression of TNFα, the critical pro-inflammatory cytokine upon HFD, this was 
completely prevented in WAT of JNK1∆NES mice (Figure 51A). Local inflammation 
accompanied by increased lipid deposition leads to reduced WAT expression of adiponectin, 
a key adipokine which increases insulin sensitivity in liver and skeletal muscle (284, 285, 
289, 290). In line with decreased expression of TNFα and reduced lipid load of WAT 
adipocytes, adiponectin mRNA expression was significantly increased in JNK1∆NES mice fed 
HFD (Figure 52B). Moreover, this increase was also detected in serum samples from 
JNK1∆NES mice (Figure 52C).  
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Figure 52: JNK1∆NES mice are protected from obesity-induced WAT inflammation 
A) Expression of TNFα in epigonadal white adipose tissue of JNK1fl/fl and JNK1∆NES mice (n=8 per group) as 
measured by Real-time PCR. B) Expression of Adiponectin in epigonadal white adipose tissue of JNK1fl/fl and 
JNK1∆NES mice (n=8 per group) as measured by Real-time PCR. C) Serum Adiponectin in control and JNK1∆NES 
mice at the age of 10 weeks was measured by ELISA (n= 8 per group). *, p ≤ 0.05; ***, p ≤ 0.001. 
 
 It has been demonstrated that adipose tissue inflammation can elicit reduced 
expression of the key adipocyte transcription factor peroxisome proliferator-activated receptor 
(PPAR) γ, which regulates adipocyte biogenesis (183, 291, 292). In line with this, adipose 
tissue samples from control animals fed HFD showed significantly reduced expression of 
PPARγ, while this was blunted in JNK1∆NES mice (Figure 53A). One of the key target genes 
of PPARγ is glucose transporter (GLUT) 4, and reduced WAT GLUT4 expression in diet-
induced obesity is thought to contribute to persistent hyperglycemia, which is one of the 
major complications of obesity and diabetes (183, 293). In line with improved glucose 
tolerance and reduced serum glucose levels, eWAT GLUT4 expression was significantly 
increased in JNK1∆NES mice fed HFD (Figure 53B). PPARγ deficiency reduces leptin 
expression (294). In accordance to mildly increased PPARγ expression, circulating leptin 
levels tended to be decreased in JNK1∆NES mice fed HFD (Figure 53C). Taken together, 
epigonadal WAT inflammation is reduced in JNK1∆NES mice, ameliorating expression of 
adiponectin, PPARγ and GLUT4. 
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Figure 53: GLUT4 expression in eWAT is increased in obese JNK1∆NES mice 
A) Expression of PPARγ in epigonadal white adipose tissue of JNK1fl/fl and JNK1∆NES mice (n=8 per group) as 
measured by real-time PCR. B) Expression of GLUT4 in epigonadal white adipose tissue of JNK1fl/fl and 
JNK1∆NES mice (n=8 per group) as measured by real-time PCR. C) Serum leptin in control and JNK1∆NES mice 
fed HFD at the age of 10 weeks was measured by ELISA (n= 7-8 per group). *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 
0.001.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                    Discussion 
   96
 
4 Discussion 
 Obesity is a major risk factor for the most prevalent causes of death in western 
societies and may pose a potential danger to future generations due to the epigenetic effects of 
maternal obesity (2, 11, 16, 19, 295-298). Hence, it is of paramount importance to gain insight 
into regulatory (patho-) physiological mechanisms in energy homeostasis.  
 It has been demonstrated that both the pancreatic hormone insulin as well as the 
adipocyte-derived hormone leptin are crucial regulators of body weight, food intake, energy 
expenditure and physical activity. Evidence exists that leptin mediates most of its effects on 
energy homeostasis, i.e. reduction of food intake, elevation of energy expenditure, and 
physical activity by acting on its receptor expressed on CNS neurons (40). While the leptin 
signalling cascade involves activation of the transcription factor STAT3, a parallel activation 
of the PI3K cascade previously known to be insulin´s main signalling cascade has also been 
described (46-48, 299).  
 The ability of insulin to modulate glucose and lipid metabolism by acting on liver, 
muscle and adipose tissue has been well documented (300-303). Findings in multiple animal 
models and humans define insulin action in the CNS as a pivotal regulator of energy 
homeostasis (56, 155, 304-308). Hence, icv application (in rodents) or intranasal application 
(in men) reduces acute and long-term food intake, and consecutively, body weight (158, 304). 
On the other hand, in parallel to peripheral resistance in diabetic patients, obesity induces 
CNS insulin and leptin resistance (184, 305). 
 Modern mouse genetics as well as studies in cohorts of patients have revealed the 
critical importance of hypothalamic neuronal populations in regulation of body weight and 
glucose homeostasis. Ablation of hypothalamic insulin or leptin receptors elevates body 
weight, whereas intrahypothalamic injection of insulin, insulin mimetics or leptin has the 
opposite effect (40, 127, 128, 309, 310).  Further investigation has revealed a critical role of 
the POMC neuron population in the hypothalamus in control of energy intake and expenditure 
both in animal models as well as in humans (131, 152, 153, 172). Hence, leptin´s and 
insulin´s ability to modulate energy homeostasis is diminished by antagonizing the receptor 
for the POMC-derived neuropeptide α-MSH (156, 311, 312).  
 The key regulator downstream of insulin-mediated PI3K activation is the protein 
kinase AKT, which has been shown to regulate protein translation, synaptic rewiring and cell 
survival in neurons (313, 314). To delineate the role of insulin-mediated signalling 
downstream of PI3K activation, the AKT-activating kinase PDK1, which is itself directly 
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downstream of the PI3K product PIP3 and only exists in one isoform, was selectively ablated 
in all POMC expressing cells (PDK1ΔPOMC mice). 
 
4.1 Inactivation of PDK1 in POMC cells 
Double-immunostaining of hypothalamic tissue sections confirmed lack of 
immunoreactive PDK1 protein in more than 90% of POMC neurons of PDK1ΔPOMC mice. 
Notably, 30% of all POMC neurons from control mice also lacked immunoreactive PDK, 
which is in line with previous findings that insulin or leptin stimulation activates the 
respective signalling cascades only in a percentage of all POMC neurons. This indicates that 
there may be several POMC subpopulations lacking for example PDK1 or STAT3, which 
cannot be distinguished as of now due to a lack of any marker protein (105). Taken together, 
PDK1ΔPOMC mice were shown to be a viable tool to study downstream signalling of the PI3K 
in hypothalamic POMC neurons, and pituitary POMC-expressing cells. 
 
4.2 PDK1 in POMC cell function 
 PDK1ΔPOMC mice presented with hyperphagia, increased body weight and impaired 
glucose metabolism during early life, while later on, body weight was normalized, insulin 
sensitivity was increased, and fat mass was even decreased compared to control animals. 
Considering that hypothalamic POMC mRNA expression was found to be decreased in young 
and adult PDK1ΔPOMC mice, which is expected to lead to chronic hyperphagia and obesity, 
another, anorexigenic input seemed to exist. Real-Time analysis as well as 
immunohistochemistry analyses demonstrated a severe reduction in pituitary POMC mRNA 
content, which was reflected in a progressive loss of circulating corticosterone in PDK1ΔPOMC 
mice over time. Upon further examination, and in contrast to unchanged hypothalamic POMC 
neuron survival, adult PDK1ΔPOMC mice presented with an 80% loss of corticotrophs (and 
melanotrophs) in the pituitary, indicating that PDK1 is essential for postnatal survival of these 
cell types. Thus, PDK1ΔPOMC mice showed a phenotype akin to human Addison´s disease. 
 Addison´s disease is invariably connected to low circulating cortisol, and can be 
caused by pituitary adenomas which block ACTH release, or adrenal insufficiency, among 
others. Symptoms include loss of appetite and weight, hypoglycemia, and increased insulin 
sensitivity, all of which were found in adult PDK1ΔPOMC mice. Similarly, mice following 
adrenalectomy are lean due to reduced hypothalamic AgRP expression and restoration of 
circulating corticosterone will normalize feeding and body weight (251). 
                                                                                                                                    Discussion 
   98
 
 Thus, in line with previous findings that restoration of corticosterone in POMC null 
mice exacerbates hyperphagia, obesity, and glucose intolerance, corticosterone treatment of 
PDK1ΔPOMC mice by implantation of osmotic minipumps increased food intake, body weight 
and fat pad size. These findings indicate that the progressive hypocortisolism due to 
corticotroph loss negated the orexigenic effect of strongly reduced hypothalamic POMC 
expression in PDK1ΔPOMC mice. 
  
4.3 The PDK1-FOXO1 axis in hypothalamic POMC expression 
 Previous findings implicated the insulin-PI3K signalling as a positive modulator of 
hypothalamic POMC expression. Consistent with this, PDK1 deficiency severely reduced 
POMC mRNA levels. Although PI3K/PDK1 signalling is known to regulate many pathways 
including SGK1, mTOR or PKC isoforms, in vitro data suggested that the AKT-target 
transcription factor FOXO1 is able to bind to and compete with leptin-activated STAT3 for 
access to adjacent binding sites on the POMC promoter (42). To examine the role of FOXO1 
in POMC neurons in vivo, a mouse with Cre-inducible expression of a FOXO1 mutant 
(FOXO1Δ256) was generated. This FOXO1 mutant lacks its transactivation domain, and 
moreover, the nuclear export sequence, sequestering it in the nucleus, where it binds to 
FOXO1 binding sites and blocks access of endogenous FOXO1 (89). Importantly, 
PDK1ΔPOMC mice expressing FOXOΔ256 in POMC cells (FOXO1Δ256:PDK1ΔPOMC mice) 
displayed normal food intake, body weight, and crucially, ameliorated hypothalamic POMC 
mRNA levels. Furthermore, expression of the anorexigenic neuropeptide cocaine and 
amphetamine regulated transcript (CART), which is expressed in a subset of POMC neurons, 
was also normalised, similar to reports published previously (50).  
 Thus, the results presented in this work suggest that insulin de-inhibits POMC 
expression by excluding FOXO1 from the nucleus, allowing leptin-activated STAT3 binding, 
resulting in increased POMC mRNA expression (Figure 54). In addition, leptin´s stimulating 
effect on electrical activity will induce α-MSH release (153). Accordingly, low levels of AKT 
activation as simulated in PDK1ΔPOMC mice diminishes leptin stimulated POMC transcription, 
since FOXO1 bound to the POMC promoter blocks STAT3 binding (42, 238). Since obese 
patients suffer from CNS insulin resistance (305), insulin signalling in POMC neurons will 
not be able to inhibit FOXO1 from binding to the POMC promoter, consolidating low levels 
of POMC expression and thus obesity. In line with this model, POMC mRNA expression is 
low and hypothalamic α-MSH release is impaired in obese mice (181).  
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Figure 54: Model of post-developmental POMC neuron activity and POMC mRNA expression  
Insulin activates PI3K signalling in POMC neurons. PI3K activation leads to PDK1-mediated phosphorylation 
and activation of AKT, which is subsequently imported into the nucleus. Here, AKT-mediated phosphorylation 
induces nuclear export of FOXO1, and thus abrogates FOXO1´s inhibition of POMC expression. Leptin-
activated STAT3 competes with FOXO1 for adjacent binding sites in the POMC promoter. Leptin may also 
induce opening of an undefined cation channel to depolarise the neuron by PI3K activation, leading to increased 
POMC neuron firing and thus α-MSH release. AKT, protein kinase B; FOXO1, forkhead box O1; IR, insulin 
receptor; ObRb, long (signalling) isoform of the leptin receptor; PI3K, phosphatidylinositol dependent kinase; 
POMC, proopiomelanocortin; STAT3, signal transducer and activator of transcription 3; +, cations. Figure 
originally prepared for (105).  
 
 Taken together, analyses reported in this work have unravelled the importance of 
PI3K-FOXO1 signalling in control of hypothalamic POMC neuron function in vivo and 
underlined the role of hypothalamic insulin signalling in control of energy homeostasis. 
 
4.4 The PDK1-FOXO1 axis in corticotroph cell survival 
 In parallel to the rescue of the hypothalamic phenotype, FOXO1Δ256:PDK1ΔPOMC mice 
might demonstrate survival of corticotrophs in the pituitary. Nonetheless, both PDK1ΔPOMC 
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mice and FOXO1Δ256:PDK1ΔPOMC mice exhibited loss of corticotrophs and circulating 
corticosterone levels. Pituitary expression analysis revealed that in young PDK1ΔPOMC mice, 
the pro-apoptotic genes Bax and Bak were already up-regulated. Additionally, Zac1, which 
had been demonstrated to be modulated in pituitary cell lines by PI3K signalling in vitro, also 
tended to be increased (254). Although these data demonstrate increased expression of pro-
apoptotic genes, further analysis with regards to protein expression of these genes, and careful 
analysis of corticotroph survival during postnatal development is necessary to understand the 
phenotype in its entirety. 
 Bax, Bak and Zac1 mRNA expression was reduced to normal levels in 
FOXO1Δ256:PDK1ΔPOMC mice. Since corticotroph survival was not rescued, PDK1-dependent, 
FOXO1-independent pathways necessary for corticotroph survival must exist. Mice lacking 
IR or PTEN in corticotrophs do not show any changes in corticotroph number, survival or 
function, therefore the ability of PDK1 to ensure corticotroph survival appears to be 
independent of insulin signalling or PI3K activation (151, 168). Since it has been noted that 
PDK1 presence is necessary for maturation and function of several PKC isoforms as well as 
SGK1, it is possible, but so far experimentally untested, that these kinases mediate the pro-
survival effect of PDK1 in corticotrophs (247). Taken together, PDK1 inhibition might 
represent a therapeutical target to treat pituitary (ACTH secreting) adenomas, in line with 
PDK1 inhibitors undergoing testing for several types of cancer (315).  
 
4.5 Hypothalamic cytokine expression in diet-induced obesity 
 CNS and hypothalamic insulin and leptin resistance is a major determinant in obesity 
and impaired glucose metabolism. Inflammatory and stress kinase signalling pathways such 
as IKK and JNK have been shown to be activated in obesity in peripheral tissues. 
Experiments in animal models have now provided evidence that JNK and IKK activation also 
occurs in the hypothalamus in diet-induced obesity (184). Hyperlipidemia and especially 
peripherally produced cytokines have been indicated in inducing hypothalamic insulin and 
leptin resistance by inducing JNK and IKK signalling, hence TNFα and IL6 protein content in 
hypothalamic tissue of diet-induced obese rats have been shown to be increased (214). 
Nonetheless, these experiments did not clarify if these cytokines originated in peripheral 
tissues such as WAT or in the hypothalamus itself.  
 In the present work, using lean and obese wild type mice, it was demonstrated that 
hypothalamic mRNA expression of inflammatory cytokines TNFα and IL6 is up-regulated.  
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 IL6 has been shown to either induce or inhibit insulin resistance in peripheral tissues 
such as liver, indicating that duration or intensity plays a role in the outcome of IL6 signalling 
(151, 219). On the other hand, IL6 null mice show adult-onset obesity, partially due to lower 
energy expenditure (221, 316). Thus, elevated IL6 levels in the hypothalamus might be 
beneficial by inducing body weight loss, in line with findings of icv IL6 treatment in rats 
(221). Notably, the leptin and insulin sensitizing effect of physical activity has been linked to 
hypothalamic IL6 signalling. Ablation of neuronal IL6 signalling will allow defining the CNS 
role of IL6 with regards to body weight and energy expenditure. 
 TNFα signalling activates JNK and IKK signalling, leading to serine phosphorylation 
of IRS proteins, and possibly also elevating expression of SOCS3, a key regulator both of 
leptin and insulin signalling in the CNS (184, 317). Nonetheless, CNS TNFα signalling has 
been linked to anorexia and cachexia during chronic diseases such as AIDS and certain types 
of cancer (216, 218). These two contradicting findings might be explained by the notion that 
during obesity, TNFα levels may be elevated by 200-300%, while in cachexic patients 
suffering from chronic diseases such as AIDS, TNFα levels have been reported to be elevated 
by up to 1200%, thus depending on the dosage, TNFα may have either orexigenic or 
anorexigenic effects (318, 319).  
 In the current work, the duality of TNFα signalling was demonstrated by icv 
injections. Whereas high dose TNFα application acutely reduced food intake and body weight 
gain during re-feeding, low dose TNFα application induced hyperphagia and escalated body 
weight gain compared to vehicle. Thus, in combination with the finding that hypothalamic 
TNFα expression is up-regulated two to three fold in diet-induced obese mice, these findings 
implicate hypothalamic TNF expression and signalling in the etiology of hyperphagia and 
obesity. Moreover, hypothalamic TNFα expression is not readily reversible by body weight 
loss due to a reduction in fat consumption.  It is well known that upon body weight loss, 
many patients suffer from “rebound” weight gain. Consequently, TNFα may play a role in 
setting an obesogenic hypothalamic environment, although it is currently unknown how under 
conditions of weight loss and improved glucose metabolism, TNFα expression is further 
increased. Interestingly, TNFα has anti-apoptotic properties in the CNS (320). Since obesity 
may induce loss of hypothalamic neurons, up-regulated TNFα in hypothalami of diet-induced 
obese mice may be a counterregulatory phenomenon to ameliorate neuronal apoptosis with 
the fallout of further inhibiting the anorexigenic effects of leptin and insulin ending in a 
vicious circle of cell loss, TNFα induction and insulin/leptin resistance (321). However, it 
remains to be delineated by which molecular mechanism TNFα induced hyperphagia/body 
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weight gain in the paradigm of re-feeding, i.e. by inducing acute insulin/leptin resistance or 
by other means, and in which cell type TNFα expression is elevated. 
  
4.6 Hypothalamic/pituitary JNK activation in obesity 
 Diet-induced obesity leads to JNK activation in several tissues, including liver, 
muscle, and adipose tissue (185, 199, 207). Similar to findings in rats, HFD increased JNK 
activity also in the hypothalamus of mice (214). Furthermore, JNK activity was also increased 
in the pituitary of obese wild type mice. To further gain insight into the role of 
hypothalamic/pituitary JNK1 activation during obesity, mice with Nestin cell-specific JNK1 
deletion were generated (JNK1ΔNes mice). The use of Nestin-Cre mice allows ablation of 
JNK1 in the two tissues where JNK activation was found to be present in diet-induced 
obesity: the CNS including the hypothalamus, and the pituitary. Therefore, JNK1 immuno-
reactivity and JNK1 mRNA expression was found to be critically reduced in the 
hypothalamus. In line with the notion that Nestin expressing stem cells generate the majority 
of somatotrophs and thyrotrophs but only 20% of all pituitary cells, pituitary JNK1 deletion 
was detected but not complete in pituitaries of JNK1ΔNes mice (264). Taken together, 
JNK1ΔNes mice are a viable tool to examine the role of CNS/pituitary JNK1 activation with 
regards to energy homeostasis. 
 
4.7 JNK1 as a regulator of somatic growth 
 JNK1 null mice are protected from diet-induced obesity including reduced fat mass 
and amelioration of hyperphagia and glucose intolerance upon HFD (199). Nonetheless, in 
that study neither food intake nor energy expenditure was reported to be changed, leaving 
open the question, how and where exactly JNK1 ablation improves body weight and 
metabolism in diet-induced obesity. 
 In the current study, ND fed JNK1ΔNes mice demonstrated significantly reduced body 
weight, although total fat content was unchanged. Food intake, when corrected for lean mass, 
was unchanged. Concurrently, JNK1ΔNes mice did not show any alterations in leptin 
sensitivity independently of diet, therefore it was concluded that CNS JNK1 activation does 
not impair leptin signalling, whereas lipid-mediated CNS IKK activation has a more 
pronounced role in the development of leptin resistance (263).  
 The lower weight seen in JNK1ΔNes mice was thus not due to changes in total body 
composition. Examination of naso-anal length led to the discovery that body length is reduced 
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by 8% under ND and 12% under HFD conditions, explaining the differences in body weight. 
Since a hypothalamus-pituitary-liver axis regulates body length and somatic growth, 
neuropeptides and hormones involved in this circuit were measured. Notably, neither GHRH 
nor somatostatin expression was altered in hypothalami of JNK1ΔNes mice, indicating that 
regulation of somatic growth is not disturbed at the level of the hypothalamus. Instead, 
expression of GH was shown to be decreased in JNK1ΔNes mice by approximately 40%. In 
line with these findings, circulating GH and IGF-1 were found to be reduced by up to 50% in 
adult JNK1ΔNes mice. Upon further examination, it was revealed that pituitary expression of 
the receptor for GHRH, GHRHR was reduced in JNK1ΔNes mice. Furthermore, the 
transcription factor PIT-1, which is crucial for GHRHR expression was down-regulated. 
Notably, immunoreactive somatotroph numbers appeared to be similar between control and 
JNK1ΔNes mice, thus reduced GH levels are not due to cell loss. Thus, it appears that pituitary 
expression of PIT-1 and GHRHR desensitised the somatotrophs to the effects of hypothalamic 
GHRH, leading to decreased release of GH, less expression and release of hepatic IGF-1, 
finally reducing linear growth. It has been demonstrated that under conditions where at least 
some GH signalling is present, somatic growth will be preserved at a high level, explaining 
why JNK1ΔNes mice show IGF-1 level reduced by up to 50%, but only a minor (8-12%) 
decrease in body length (322).  
 There is a clear correlation between energy status and somatic growth. Wild type mice 
show increased linear growth when fed HFD, and overweight children grow faster compared 
to controls (323). Interestingly, the melanocortin circuit has been shown to be involved in this 
phenomenon. POMC and MC4R null mice have an increased body length, and patients with 
MC4R mutations show an increase in average height (134, 138, 324). Nonetheless, insight 
into the pathways involved in this phenomenon has been limited. 
 In the current study, a role for JNK1 in regulation of pituitary expression of GH, 
GHRHR and PIT1 was revealed. Diet-induced obese controls showed elevated pituitary 
expression of GHRHR and GH, which was abrogated in JNK1ΔNes mice. These findings are in 
line with a previous report, which demonstrated a specific increase in GH expression in HFD-
fed young mice (accompanied by increased somatic growth), although in that study, the 
authors did not measure GHRHR expression (268). Thus, these findings indicate that JNK1 
signalling in somatotroph regulates the GH/IGF1 axis, and that this circuit might sense caloric 
overabundance through activation of JNK1. 
 Partially impeded by the lack of pituitary cell lines expressing endogenous GHRHR, 
signalling cascades involved in GHRHR gene transcription are not well understood. Studies 
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in patients have revealed a significant role for PIT-1-mediated transcriptional activation (325). 
Concerning PIT-1 expression, several AP-1 binding sites in its promoter exist, and in 
addition, cAMP response elements in the PIT-1 promoter may be transactivated by MAPK 
(including JNK) signalling  (326).  Therefore, PIT-1 expression may be directly regulated by 
JNK1-dependent activation of the c-Jun/AP-1 class of transcription factors, although this 
hypothesis has not been experimentally addressed yet. Here, c-Jun ablation specifically in the 
somatotroph lineage may be helpful to delineate its function in PIT-1 and/or GHRHR 
expression, since both GHRHR-Cre transgenic mice as well as mice with loxP-flanked c-Jun 
alleles have been generated (327, 328). Moreover, it remains undetermined which stimulus 
activates JNK signalling in somatotrophs to regulate somatic growth. In the current study, 
elevated levels of ER stress markers were detected in pituitaries of HFD fed mice. Thus, 
hypothetically, ER stress, for example induced by elevated circulating lipid concentrations, 
may play a role in regulation of somatic growth by activation of JNK1. Future work will be 
necessary to understand the upstream activators and downstream targets of pituitary JNK1 
signalling.  
  
4.8 JNK1 as a negative regulator of the thyrotrophic axis 
 JNK1ΔNes mice were found to show mildly increased energy expenditure. Surprisingly, 
pituitary expression of TSHβ was found to be increased by approximately 300%. In line with 
this finding, circulating free T3 levels were elevated in JNK1ΔNes mice, and BAT UCP1 levels 
were mildly increased. Concurrently, BAT morphology was changed in JNK1ΔNes mice in the 
way of smaller adipocytes, indicating higher levels of lipid expenditure, or differences in lipid 
deposition in BAT compared to other tissues. Notably, neither respiratory quotient nor body 
composition was different between control and JNK1ΔNes mice, indicating that although 
lipolysis appears to be increased in BAT, glucose catabolism must be proportionally increased 
as well. 
 Pituitary TSHβ expression is under control of TRH, which itself is released by PVN 
neurons (329). Since hypothalamic TRH levels were similar in control and JNK1ΔNes mice, 
increased TSHβ may be due to a pituitary-autonomous phenomenon. Indeed, TRHR 
expression was found to be elevated in JNK1ΔNes mice. In line with the notion of a pituitary-
autonomous effect of JNK1 signalling, JNK inhibitor, but not PI3K or ERK inhibitor 
treatment increased TRHR expression in vitro. Thus, these data suggest that thyrotrophic 
JNK1 signalling may reduce TRHR expression, resulting in decreased TRH sensitivity and 
TSHβ expression, and consequently, reduced energy expenditure.  
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 Control of TRHR expression appears to be complex as both PIT-1 and glucocorticoid 
receptor binding elements have been demonstrated in the TRHR promoter (279). Nonetheless, 
in vitro-based work indicates a PIT-1 independent mechanism involved in JNK1-mediated 
control of TRHR expression. While JNK inhibition was sufficient to induce TRHR expression 
in vitro, PIT-1 expression was unaltered. Since experimental evidence exists that direct JNK-
mediated phosphorylation negatively regulates glucocorticoid receptor signalling, and 
glucocorticoid receptor signalling increases TRHR expression in vitro, future work will be 
aiming to examine the status of glucocorticoid signalling in the pituitary of JNK1ΔNes mice 
(330, 331). 
  
4.9 JNK1 action and hypothalamic insulin sensitivity 
 Hypothalamic insulin signalling has been shown to inhibit peripheral glucose 
production, and induce glucose uptake, thereby improving glucose tolerance (151, 166). 
Hypothalamic JNK signalling may induce local insulin resistance, which subsequently would 
lead to glucose and insulin intolerance in peripheral tissues. In line with this idea, JNK 
activity in hypothalamic tissue of obese mice was found to be increased.  
 While leptin´s ability to reduce body weight gain and insulin sensitivity was 
indistinguishable between control and JNK1ΔNes mice, icv administration of insulin exerted 
potent anorexigenic effects only in JNK1ΔNes mice and independently of diet, while control 
animals did not show any effect on food intake or body weight at the insulin dose chosen. 
Thus, JNK1ΔNes mice show elevated CNS insulin efficacy. In addition, hypothalamic 
activation of insulin´s signalling cascade in both groups fed HFD was evaluated using 
phosphorylation (= activation) of AKT as a marker. In line with the findings on food intake 
and body weight, icv insulin application induced more than three-fold higher hypothalamic 
AKT activation in JNK1ΔNes mice compared to controls, further demonstrating that PI3K 
signalling is negatively affected by hypothalamic JNK1 signalling, possibly due to serine 
phosphorylation of IRS residues (201). Taken together, JNK1 regulates hypothalamic insulin 
but not leptin sensitivity. 
 
4.10 Systemic effects of CNS/pituitary JNK1 signalling 
 JNK1ΔNes mice showed reduced circulating glucose levels both in the fasted and 
random fed state, indicating improved glycemic control. In line with this, circulating insulin 
levels were reduced, and JNK1ΔNes mice showed improved systemic insulin sensitivity. 
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 Several lines of experimental evidence indicate that decreased HGP is responsible for 
the improved glucose levels. Hypothalamic insulin signalling regulates HGP by increasing 
hepatic IL6 levels (151, 163).  In parallel to improved hypothalamic insulin sensitivity, 
hepatic IL6 expression was elevated in JNK1ΔNes mice. Secondly, glucose levels in JNK1ΔNes 
mice remained low when injected with a substrate for gluconeogenesis (pyruvate), further 
pointing to a reduction in hepatic glucose output. Lastly, hepatic insulin action itself was 
improved in JNK1ΔNes mice under conditions of diet-induced obesity. Since GH signalling 
negatively affects hepatic insulin sensitivity, hypothalamic insulin signalling and the 
reduction of circulating GH may additively improve liver insulin action (332, 333). 
 Besides glucose metabolism, profound changes in lipid metabolism and storage were 
detected in JNK1ΔNes mice. Hence, hepatic steatosis was prevented in HFD fed JNK1ΔNes 
mice. Hepatic steatosis may increase the risk of developing hepatocarcinomas, and liver lipid 
content has also been directly connected to hepatic insulin resistance (334, 335). Thus, in 
addition to improved hypothalamic insulin signalling and reduced GH levels, reduced hepatic 
lipogenesis or elevated lipoprotein secretion may be an underlying factor in the decreased 
hepatic glucose output demonstrated in JNK1ΔNes mice. Nonetheless, since liver insulin 
resistance may induce hepatic accumulation of lipids, it remains unknown if reduced steatosis 
is cause or effect of improved hepatic insulin action in JNK1ΔNes mice (336). 
 Since a decrease in hepatic lipid content may be due to increased lipid deposition in 
adipose tissue, WAT structure and function was assessed in JNK1ΔNes mice. In line with 
unchanged total body composition, ND fed JNK1ΔNes mice showed the same relative 
epigonadal fat mass. Nonetheless, analysis of adipocyte structure revealed an increase in 
adipocyte size in ND fed JNK1ΔNes mice. Koch and colleagues have demonstrated that chronic 
low-level CNS insulin application will increase adipocyte size and epigonadal fat mass (161). 
In that study, the authors demonstrated that WAT LPL expression was up-regulated by CNS 
insulin action (161). LPL catalyzes fatty acid entry into adipocytes (86). In line with the 
notion that increased CNS insulin action might be causing the increased adipocyte size, 
JNK1ΔNes mice showed a tendency for increased LPL expression. Nonetheless, since GH 
induces adipocyte insulin resistance, increased insulin-mediated inhibition of lipolysis due to 
low circulating GH may be a second pathway explaining the increased size of adipocytes 
(337). 
 In obese patients as well as animal models, adipocyte volume is increased due to lipid 
influx. Consequently, adipocytes of HFD fed control animals showed a massive increase in 
adipocyte size. Notably, adipocyte size was unchanged between ND and HFD fed JNK1ΔNes 
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mice. Further analysis of lipid enzyme expression revealed significantly increased LPL and 
HSL mRNA expression in JNK1ΔNes mice under HFD conditions. HSL-mediated hydrolysis 
of triglycerides is the rate-limiting step in mobilisation of fat stores. Notably, the disability of 
adipocytes of obese patients to release lipids into the bloodstream is thought to lead to lipid 
overload, ending in adipocyte apoptosis, and further recruitment of macrophages (288). Thus, 
enzymes necessary for lipid uptake (LPL) and lipid release (HSL) are up-regulated, indicating 
improved and dynamic lipid disposition in eWAT of JNK1ΔNes mice. Conversely, fasting 
induced a 40% reduction in eWAT mass of JNK1ΔNes mice, while control animals did not 
show a significant eWAT weight loss.  
 In accordance with the eWAT showing signs of improved function (i.e. ameliorated 
LPL and HSL expression under HFD conditions), adiponectin expression and circulating 
adiponectin levels were increased in JNK1ΔNes mice when challenged with HFD. Adiponectin 
has been shown to be essential for hepatic insulin sensitivity, and its obesity-induced 
reduction is one of the key events in development of DM (289). Expression of PPARγ, a key 
transcription factor in adipocyte metabolism and its target gene GLUT4 were also found to be 
increased (292, 294). Since increased GLUT4 levels will raise glucose uptake, adipocytes 
may act as a glucose sink, which together with reduced HGP, improves glucose tolerance in 
JNK1ΔNes mice. 
 Taking into account the reduced hepatic lipid content and decreased circulating 
glucose levels, it appears that lipids and glucose are redirected to eWAT of JNK1ΔNes mice, 
mediated by up-regulated expression of LPL and GLUT4, as a consequence of increased CNS 
insulin action and reduced circulating GH levels. At the same time, adipocyte lipid overload is 
inhibited by HSL-mediated lipid hydrolysis as well as increased adipocyte biogenesis 
mediated by PPARγ, precluding adipocyte lipid overload and thus in combination preventing 
local inflammation and maintaining adiponectin expression.  
 In addition to these local effects, the increased thyroid tone likely plays into the 
complex phenotype of JNK1ΔNes mice. Mice with a severe reduction of BAT mass are insulin 
resistant and suffer from obesity, hyperlipidemia, and WAT inflammation (281). 
Correspondingly, the increased thyroid tone may partially be responsible for the overall 
improvement of hepatic and eWAT function.  
 Taken together, JNK1ΔNes mice are protected from obesity-associated glucose 
intolerance, hepatic steatosis and adipose tissue inflammation. Although they are also 
hypersensitive to the anorexigenic effects of insulin, they are unexpectedly not protected from 
obesity per se, and do not eat less compared to control animals when challenged with HFD. 
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 Of note, PPARγ has been shown to decrease leptin expression, and was moderately 
increased in eWAT of JNK1ΔNes mice (293, 294). In comparison with control animals, 
circulating leptin levels tended to be decreased in JNK1ΔNes mice under HFD conditions and 
thus were no longer correlated with adipose tissue mass, while systemic and central leptin 
sensitivity of these mice was clearly unaltered. 
 Another cause of the reduced circulating leptin and/or the unchanged obesity might lie 
in the increased thyroid tone in JNK1ΔNes mice. Reduced GH and/or IGF-1 levels would be 
expected to increase leptin levels, in contrast to what is seen in JNK1ΔNes mice (338, 339). 
While hypothyroidism induces weight gain and obesity due to reduced energy expenditure, 
T3 has some orexigenic properties, possibly to offset its ability to considerably induce energy 
expenditure (281, 340). In addition, hyperthyroidism has been shown to decrease WAT leptin 
expression through the activation of adrenergic signalling (341, 342). Taken together, the 
results presented in this work suggest that the elevated thyroid tone in combination with 
higher glucose and lipid uptake into WAT counterbalances the anorexic drive induced by 
increased CNS insulin sensitivity, resulting in unchanged hypothalamic neuropeptide 
expression, food intake and body composition. Future studies will aim to further delineate the 
complex roles of hypothalamic and pituitary JNK1 function. 
 
4.11 Caloric restriction, aging and JNK1 
 A phenotype of reduced activation of the somatotrophic axis in combination with 
improved glucose tolerance and insulin sensitivity is very similar to what is seen in animal 
models undergoing caloric restriction (CR), which is the only intervention repeatedly shown 
to prolong life. Thus, CR improves glucose metabolism, insulin sensitivity and importantly, 
prolongs life span and reduces aging-associated disabilities in multiple animal models (343, 
344). Molecular analysis has revealed that decreased activation of the somatotrophic axis is 
necessary for the beneficial effects of CR (345, 346). In a similar vein, aging-induced cellular 
GH/IGF-1 resistance confers beneficial resistance against oxidative stress (347). In the 
present study, the crucial role for CNS/pituitary JNK1 in regulation of the somatotrophic and 
thyrotrophic axis as well as CNS insulin sensitivity was demonstrated. Although these results 
point at JNK1 as a pharmacological target to mimic CR, careful analysis of life span in 
JNK1ΔNes mice and possible side effects of specific JNK1 inhibitors in vivo will be necessary 
to substantiate this notion. 
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4.12 Perspective 
 The obesity pandemic in combination with a rapidly aging society endangers 
developed societies by severely increasing health costs, as well as reducing quality of life for 
people of all age groups. The molecular and endocrine bases for development of obesity and 
aging are mostly unknown at this time, although control of body weight, insulin sensitivity 
and aging-related diseases are clearly linked.  
 In the present study, inactivation of PDK1 and subsequently inhibiting FOXO1 
function in POMC cells revealed new insights into development of CNS insulin and leptin 
resistance as well as regulation of energy homeostasis by both hormones. In addition, this 
study expanded the knowledge of regulation of pituitary cell survival with implications in the 
treatment of pituitary cancer. 
 Moreover, ablation of JNK1 in the CNS and the pituitary uncovered the crucial role of 
a kinase previously connected to insulin resistance and inflammatory signalling in regulation 
of somatic growth and thyroid function, and thus linked ambient energy levels to linear 
growth on a molecular level. Furthermore, since low circulating GH and IGF-1 levels are 
implied to confer the beneficial effects of CR, further analysis will define the role of CNS and 
pituitary JNK1 signalling in the context of aging. Insight into the molecular mechanisms 
linking insulin resistance and inflammation-associated cellular stress are necessary to uncover 
new treatments to treat the plethora of aging- and obesity-related diseases in the 21th century. 
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5 Summary 
 Insulin and leptin action in the central nervous system (CNS) controls food intake, 
energy expenditure and glucose metabolism, partially by regulating the activity of 
hypothalamic proopiomelanocortin (POMC) neurons. Moreover, insulin- and leptin-
stimulated phosphatidylinositol-3 kinase (PI3K) activation has been demonstrated to play a 
critical role in the control of energy homeostasis. To delinearize the importance of pathways 
downstream of PI3K specifically in POMC cell regulation, mice with selective inactivation of 
3-phosphoinositide-dependent protein kinase-1 (PDK1) in POMC-expressing cells 
(PDK1ΔPOMC mice) were generated. PDK1ΔPOMC mice initially display hyperphagia, increased 
body weight and impaired glucose metabolism caused by reduced hypothalamic POMC 
expression. In contrast, older PDK1ΔPOMC mice exhibit normalized food intake and body 
weight as well as enhanced insulin and glucose sensitivity, due to a progressive loss of 
POMC-expressing corticotrophs in the pituitary and subsequent severe hypocortisolism. 
Expression of a dominant negative mutant of FOXO1 specifically in POMC cells is sufficient 
to prevent initial hyperphagia, transiently increased body weight and reduced hypothalamic 
POMC expression in PDK1ΔPOMC mice, but cannot restore regular pituitary function. These 
results reveal important but differential roles for PDK1 signaling in hypothalamic and 
pituitary POMC cell function and survival in control of energy homeostasis and stress 
response.  
 To understand potential pathomechanisms involved in neuronal insulin and leptin 
resistance, the effect of obesity on hypothalamic expression of inflammatory mediators was 
examined. High-fat feeding was found to induce hypothalamic expression of cytokines such 
as tumor necrosis factor α, which was not readily reversible by switching to low-fat diet. 
Since cytokines and lipids are known to activate c-Jun N-terminal kinases (JNKs), mice with 
JNK1 deficiency in Nestin-expressing cells (which include neurons and pituitary stem cells) 
were generated (JNK1ΔNes mice).   
 These mice demonstrated increased hypothalamic insulin sensitivity, as well as 
reduced activation of the somatotrophic axis and elevated activation of the thyrotrophic axis, 
resulting in improved improved glucose tolerance, elevated systemic insulin sensitivity, and 
were protected against obesity-induced hepatosteatosis and adipose tissue dysfunction. Taken 
together, obesity-induced JNK1 activation in the hypothalamus and pituitary is a crucial event 
in the induction of CNS insulin resistance and systemic glucose intolerance caused by obesity.
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6 Zusammenfassung 
 Insulin und Leptin-aktivierte Signalkaskaden im zentralen Nervensystem (ZNS) 
regulieren Nahrungsaufnahme, Energieverbrauch und Blutzuckerkonzentrationen, 
insbesondere durch ihren Effekt auf hypothalamische Proopiomelanokortin (POMC)-
Neurone. Insulin und Leptin stimulieren die Phosphatidylinositol-3 Kinase (PI3K), und diese 
Aktivierung ist notwendig für die gewichtssenkenden Effekte von beiden Hormonen. Um den 
Effekt der Signalkaskaden abwärts von PI3K insbesondere in POMC-Neuronen zun 
untersuchen, wurden Mäuse mit Inaktivierung der 3-Phosphatidylinositol-abhängigen Kinase 
(PDK1) in POMC-exprimierenden Zellen (PDK1ΔPOMC Mäuse) generiert. Junge PDK1ΔPOMC 
Mäuse zeigten erhöhte Nahrungsaufnahme, Körpergewicht und Blutzucker verursacht durch 
erniedrigte hypothalamische POMC Expression.  Adulte PDK1ΔPOMC Mäuse hingegen 
demonstrierten normale Nahrungsaufnahme und Körpergewicht, und erhöhte 
Insulinsensitivität sowie Glukosetoleranz. Dies war auf einen progressiven Verlust der 
POMC-exprimierenden corticotrophen Zellen in der Hypophyse zurückzuführen, was zu 
krankhaft niedrigen Kortisol-Konzentrationen führte. Expression einer dominant-negativen 
FOXO1-Mutante in POMC-Zellen normalisierte Nahrungsaufnahme, Körpergewicht und 
hypothalamische POMC Expression, jedoch verhinderte nicht den Verlust der corticotrophen 
Zellen der Hypophyse. Zusammengenommen haben diese Ergebnisse die differentielle Rolle 
von PDK1 in der hypothalamischen Regulation des Energiehaushalts sowie der  Stressantwort 
der Hypophyse  aufgedeckt. Um die Mechanismen der Adipositas-assoziierten ZNS Leptin- 
und Insulinresistenz zu verstehen, wurde der Effekt von Adipositas auf die hypothalamische 
Expression von Zytokinen untersucht. Eine fettreiche Diät erhöhte die Expression von 
Zytokinen wie Tumor Nekrose Factor α,  was nicht  kurzfristig durch eine fettarme Ernährung 
umkehrbar war. Da Zytokine und Fette bekanntermaßen die c-Jun N-terminalen Kinasen 
(JNKs) aktivieren, wurden Mäuse  mit JNK1-Defizienz in Nestin-exprimierenden Zellen (d.h. 
im ZNS sowie in Stammzellen der Hypophyse) generiert (JNK1ΔNes Mäuse). Diese  Mäuse  
zeigten erhöhte hypothalamische Insulinsensitivität, reduzierte Aktivität der somatotrophen 
Achse und gesteigerte Aktivität der thyrotrophen Achse,  was zu einer verbesserten 
systemischen Insulinsensitivität führte. JNK1ΔNes Mäuse waren auch vor Adipositas-
induzierter  Fettleber sowie Fettgewebestörungen geschützt. Zusammengenommen haben 
diese Daten gezeigt, dass Adipositas-mediierte JNK1 Aktivierung im Hypothalamus sowie 
der Hypophyse ein entscheidender Punkt in der Entstehung von Insulinresistenz und 
Glukoseintoleranz ist. 
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